



UNIVERSITI PUTRA MALAYSIA

***RNA INTERFERENCE SILENCING OF INTERLEUKIN-6 IN MESENCHYMAL
STROMAL CELLS AND ANTITUMOUR EFFICACY AGAINST MULTIPLE
MYELOMA CELLS***

TEOH HOON KOON

FPSK(p) 2015 24



**RNA INTERFERENCE SILENCING OF INTERLEUKIN-6 IN
MESENCHYMAL STROMAL CELLS AND ANTITUMOUR EFFICACY
AGAINST MULTIPLE MYELOMA CELLS**



By

TEOH HOON KOON

**Thesis Submitted to the School of Graduate Studies,
Universiti Putra Malaysia, in Fulfilment of the
Requirements for the Degree of Doctor of Philosophy**

August 2015

All materials contained within the thesis, including without limitation text, logos, icons, photographs and all other artwork, is copyright material of Universiti Putra Malaysia unless stated otherwise. Use may be made of any material contained within the thesis for non-commercial purposes from the copyright holder. Commercial use of material may only be made with the express, prior, written permission of Universiti Putra Malaysia.

Copyright © Universiti Putra Malaysia



Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfilment
of the requirement for the degree of Doctor of Philosophy

**RNA INTERFERENCE SILENCING OF INTERLEUKIN-6 IN
MESENCHYMAL STROMAL CELLS AND ANTITUMOUR EFFICACY
AGAINST MULTIPLE MYELOMA CELLS**

By

TEOH HOON KOON

August 2015

Chair: Associate Professor Chong Pei Pei, PhD
Faculty: Medicine and Health Sciences

Studies demonstrated that mesenchymal stromal cells (MSC) from bone marrow (BM) stroma produced high concentrations of interleukin-6 (IL-6) that promoted multiple myeloma growth. In view of the failure of IL-6 monoclonal antibody therapy to demonstrate substantial clinical responses in early clinical trials, more effective methods are needed to disrupt the favourable microenvironment provided by the BM. In this study, RNA interference (RNAi)-mediated silencing of IL-6 in MSC and the efficacy of these modified MSC on U266 multiple myeloma cell growth inhibition *in vitro* and *in vivo* were evaluated. IL-6 silencing in MSC was induced using two different pathways: (1) direct administration of synthetic IL-6 siRNA using lipofectamine 2000 transfection and (2) vector-based adenovirus vector encoding IL-6 shRNA. Firstly, IL-6 protein in MSC was significantly suppressed to 36.7% and 39.4% post IL-6 siRNA transfection and IL-6 shRNA transduction respectively by 120 h compared to control MSC (100%) ($P < 0.05$, T-test with $n = 3$ independent replicates). MSC remained viable and maintained their immunophenotypic profile and trilineage differentiation capacities similar to control MSC indicating no unanticipated phenotypic changes or cellular toxicity post IL-6 silencing. Secondly, *in vitro* and *in vivo* growth inhibition of U266 cells were shown in the presence of MSC transfected with IL-6 siRNA or transduced with IL-6 shRNA. *In vitro* results from three independent replicates showed that MSC transfected with IL-6 siRNA significantly inhibited U266 growth to 52.8% and 66.9% by day three through cell-substrate and cell-cell interactions respectively ($P < 0.05$, ANOVA). MSC transduced with IL-6 shRNA also inhibited U266 growth significantly to 53.1% and 74.4% by day five through cell-substrate and cell-cell interactions respectively ($P < 0.05$, ANOVA). Results from subsequent *in vivo* study showed significant reduction of U266 average tumour volume to 232.3 mm³ and 331.7 mm³ by day 21 in nude mice co-injected with MSC transfected with IL-6 siRNA and MSC transduced with IL-6 shRNA respectively compared to control MSC (1162.9 mm³) ($P < 0.05$, ANOVA with $n = 5$ mice/group). Further histological

analysis also showed increasing presence of lymphocytic infiltrates and significant decrease of mitotic index from 21 in tumours co-injected with control MSC to 15 in both U266 tumours co-injected with MSC transfected with IL-6 siRNA and MSC transduced with IL-6 shRNA indicating reduction of proliferating cells in the treated tumours ($P < 0.05$, ANOVA with $n = 3$ slides/group). In conclusion, both RNAi pathways were equally effective in suppressing IL-6 expression in MSC and displayed *in vitro* and *in vivo* antitumor efficacy against U266 cells. These findings support the feasibility of using RNAi as an alternative approach for targeted suppression of IL-6 in MSC to inhibit multiple myeloma cell growth.



Abstrak thesis yang dikemukakan kepada Senat Universiti Putra Malaysia
Sebagai memenuhi keperluan untuk ijazah Doktor Falsafah

**PELENYAPAN GEN INTERLEUKIN-6 DALAM SEL STEM MESENKIMA
STROMA DAN EFIKASI ANTITUMOR TERHADAP SEL MIELOMA
MULTIPEL**

Oleh

TEOH HOON KOON

Ogos 2015

Pengerusi: Profesor Madya Chong Pei Pei, PhD
Fakulti: Perubatan dan Sains Kesihatan

Kajian terdahulu menunjukkan sel stem mesenkima stroma (MSC) daripada stroma sumsum tulang menghasilkan banyak interleukin-6 (IL-6) untuk pertumbuhan sel mieloma multipel. Kaedah yang lebih efektif untuk mengatasi persekitaran mikro optimal yang disediakan sumsum tulang diperlukan akibat kekurangan keberkesanan terapi antibodi monoklonal IL-6 dalam menghasilkan respon klinikal yang signifikan. Dalam kajian ini, pelenyapan gen IL-6 MSC berasaskan interferensi RNA (RNAi) dan efikasi MSC yang dimodifikasi ini dalam perencatan pertumbuhan sel mieloma multipel disiasat. Pelenyapan gen IL-6 MSC dilakukan menerusi dua aliran: (1) pemindahan langsung siRNA sintetik IL-6 dengan transfeksi Lipofectamine 2000 dan (2) berasaskan vektor adenovirus yang mengkod shRNA IL-6. Pertama, protein IL-6 berkurangan kepada 36.7% dan 39.4% selepas transfeksi siRNA IL-6 dan transduksi shRNA IL-6 masing-masing selepas 120 jam ($P < 0.05$, T-test dengan $n =$ tiga replikat bebas). MSC masih viabel dan mengekalkan profil immunofenotipik serta kapasiti pembezaan tiga "lineage" sama seperti MSC kontrol menandakan tiada perubahan fenotip serta ketoksikan selular selepas pelenyapan gen IL-6. Kedua, perencatan pertumbuhan sel U266 *in vitro* dan *in vivo* ditunjukkan MSC selepas transfeksi siRNA IL-6 ataupun transduksi shRNA IL-6. Hasil kajian *in vitro* tiga replikat bebas menunjukkan MSC, selepas transfeksi siRNA IL-6, merencat pertumbuhan sel U266 dengan signifikan kepada 52.8% dan 66.9% pada hari ketiga menerusi interaksi sel-substrat dan sel-sel masing-masing ($P < 0.05$, ANOVA). MSC selepas transduksi shRNA IL-6 turut merencat pertumbuhan U266 dengan signifikan kepada 53.1% dan 74.4% pada hari kelima menerusi interaksi sel-substrat dan sel-sel masing-masing ($P < 0.05$, ANOVA). Hasil kajian *in vivo* seterusnya menunjukkan pengurangan signifikan purata isipadu tumor U266 ke 232.3 mm³ dan 331.7 mm³ pada hari ke-21 dalam tikus imun kompromi yang disuntik dengan MSC selepas transfeksi siRNA IL-6 dan transduksi shRNA IL-6 masing-masing berbanding MSC kontrol (1162.9 mm³) ($P < 0.05$, ANOVA dengan $n = 5$ tikus/kumpulan). Analisis histologi selanjut menunjukkan peningkatan infiltrasi limfositik dan pengurangan

signifikan indek mitosis daripada 21 dalam tumor U266 yang disuntik dengan MSC kontrol kepada 15 dalam kedua-dua tumor yang disuntik dengan MSC selepas transfeksi siRNA IL-6 ataupun transduksi shRNA IL-6 menandakan pengurangan sel berproliferasi dalam tumor tersebut ($P < 0.05$, ANOVA dengan $n = 3$ slaid/kumpulan). Kesimpulannya, kedua-dua aliran RNAi adalah sama-sama efektif dalam pengurangan ekspresi IL-6 MSC dan mempamerkan efikasi antitumor *in vitro* dan *in vivo* yang setara ke atas sel mieloma multipel. Hasil kajian setakat ini menyokong kebolehlaksanaan penggunaan RNAi sebagai alternatif untuk pengurangan terarah IL-6 dalam MSC untuk perencatan pertumbuhan sel mieloma multipel.



ACKNOWLEDGEMENTS

Firstly, I would like to thank the National Cancer Council of Malaysia, Scientex Foundation Malaysia and Universiti Kebangsaan Malaysia (UKM) for funding this study. Secondly, I would like to extend my deepest appreciation and gratitude to my Supervisory Committee Members: Assoc. Prof. Dr. Chong Pei Pei, Assoc. Prof. Dr. Maha Abdullah, Prof. Dr. Zamberi Sekawi, Prof. Emeritus Dr. Cheong Soon Keng and Assoc. Prof. Dr. Leong Chooi Fun for their invaluable advice and constructive criticisms throughout the course of this study. To Prof. Emeritus Dr. Cheong and Assoc. Prof. Dr. Leong, a special thank you to the both of them for giving me the chance to work in their respective organisation and laboratory. It has been a real pleasure and a positive learning experience working with the both of them.

I would also like to thank the following individuals for their help and technical assistance during the course of this study. To Assoc. Prof. Dr. Tan Geok Chin and his team at the Department of Pathology, UKM Medical Centre, for technical assistance on reviewing the slides and immunohistochemical staining. To Ms. Teh Hui Xin, the Science Officer from Universiti Tunku Abdul Rahman (UTAR) for her kind assistance rendered during my work at the Animal Holding Facility, Faculty of Medicine and Health Sciences, UTAR (Bandar Sungai Long Campus). In addition, I would like to record my sincere thanks to the staffs of the Stem Cell Transplantation Unit and Haemostasis Unit, UKM Medical Centre: Pn. Aini Ardena, Pn. Habshah Aziz, Pn. Roslizawati Md. Rosle, Pn. Mahfuzha Mustafa, Cik Mazlina Mohd. Aziz, Pn. Siti Rahidah Barber, Cik Siti Rohana Abd Rahman, Cik Khin Moe Myint, En. Sayed Adlisham Sayed Ali and En. Mohd. Akhir Che Mat for their kind assistance and friendship during the course of this study.

Postgraduate life is no doubt challenging and stressful. However, the presence of fabulous labmates and friends made the journey immensely tolerable and rewarding. To Ms. Liew Lee Chuen, Ms. Ng Wei Yi, Dr. Rachel Mok Pooi Ling, Ms. Erica Choong Pei Feng, Pn. Rohayu Mohammad, Mr. Wong Chee Yin, Mr. Masro Mohamed, Ms. Nalini Devi Verusingam, Mr. Lee Han Chung and Ms. Tan Yuen Fen,; thank you for being a friend and for all the helpful discussions. A special thank you is also extended to Ms. Liew, Ms. Ng, Dr. Mok and Ms. Choong for the many, many great moments that we have shared over the last few years.

On a personal note, I would also like express my deepest gratitude to my family especially my beloved parents: Mr. Teoh Lai Sing and Mdm. Lam Lai Fong and my two sisters, Ms. Teoh Hoon Ngee and Ms. Teoh Hoon Chin for their unwavering love and support over the years. I am forever thankful for their kind understanding throughout the course of my study. Last but not least, the successful completion of this study would have been impossible without the presence of Mr. Lim Siang Hui and his relentless support, understanding and patience over the years. Thank you for believing in me and for always making me see the silver linings in each situation which gave me the confidence to complete this study. No words can express my gratitude and I am forever grateful for your presence in my life.

I certify that a Thesis Examination Committee has met on 18 August 2015 to conduct the final examination of Teoh Hoon Koon on her thesis entitled "RNA Interference Silencing of Interleukin-6 in Mesenchymal Stromal Cells and Antitumour Efficacy Against Multiple Myeloma Cells" in accordance with the Universities and University Colleges Act 1971 and the Constitution of the Universiti Putra Malaysia [P.U.(A) 106] 15 March 1998. The Committee recommends that the student be awarded the Doctor of Philosophy.

Members of the Thesis Examination Committee were as follows:

Loh Su Peng, PhD

Associate Professor
Faculty of Medicine and Health Science
Universiti Putra Malaysia
(Chairman)

Rozita binti Rosli, PhD


Professor
Institute of Bioscience
Universiti Putra Malaysia
(Internal Examiner)

Norshariza binti Nordin, PhD

Senior Lecturer
Faculty of Medicine and Health Science
Universiti Putra Malaysia
(Internal Examiner)

Chng Wee Joo, PhD

Associate Professor
National University Cancer Institute Singapore
Singapore
(External Examiner)



ZULKARNAIN ZAINAL, PhD

Professor and Deputy Dean
School of Graduate Studies
Universiti Putra Malaysia

Date: 22 September 2015

This thesis was submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfilment of the requirement for the degree of Doctor of Philosophy. The members of the Supervisory Committee were as follows:

Chong Pei Pei, PhD

Associate Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Chairman)

Maha Abdullah, PhD

Associate Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Member)

Zamberi Sekawi, PhD

Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Member)

Leong Chooi Fun, MBBS

Associate Professor
Faculty of Medicine
Universiti Kebangsaan Malaysia
(Member)

Cheong Soon Keng, MBBS

Professor
Faculty of Medicine and Health Sciences
Universiti Tunku Abdul Rahman
(Member)

BUJANG BIN KIM HUAT, PhD

Professor and Dean
School of Graduate Studies
Universiti Putra Malaysia

Date:

Declaration by graduate student

I hereby confirm that:

- this thesis is my original work;
- quotations, illustrations and citations have been duly referenced;
- this thesis has not been submitted previously or concurrently for any other degree at any other institutions;
- intellectual property from the thesis and copyright of the thesis are fully-owned by Universiti Putra Malaysia, as according to the Universiti Putra Malaysia (Research) Rules 2012;
- written permission must be obtained from the supervisor and the office of the Deputy Vice-Chancellor (Research and Innovation) before the thesis is published (in the form of written, printed or in electronic form) including books, journals, posters, reports, lecture notes, learning modules or any other materials as stated in the Universiti Putra Malaysia (Research) Rules 2012;
- there is no plagiarism or data falsification/fabrication in the thesis, and scholarly integrity is upheld as according to the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) and the Universiti Putra Malaysia (Research) Rules 2012. The thesis has undergone plagiarism detection software.

Signature: _____

Date: _____

Name and Matric No.: Teoh Hoon Koon GS25254

Declaration by Members of Supervisory Committee

This is to confirm that:

- the research conducted and the writing of this thesis was under our supervision;
- supervision responsibilities as stated in the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) are adhered to.

Signature: _____
Name of
Chairman of
Supervisory
Committee: Chong Pei Pei, PhD

Signature: _____
Name of
Member of
Supervisory
Committee: Maha Abdullah, PhD

Signature: _____
Name of
Member of
Supervisory
Committee: Zamberi Sekawi, PhD

Signature: _____
Name of
Member of
Supervisory
Committee: Leong Chooi Fun, MBBS

Signature: _____
Name of
Member of
Supervisory
Committee: Cheong Soon Keng, MBBS

TABLE OF CONTENTS

	Page
ABSTRACT	i
ABSTRAK	iii
ACKNOWLEDGEMENTS	v
APPROVAL	vi
DECLARATION	viii
LIST OF TABLES	xiii
LIST OF FIGURES	xiv
LIST OF APPENDICES	xviii
LIST OF ABBREVIATIONS	xix
CHAPTER	
1 INTRODUCTION	1
1.1 Overview	1
1.2 Aims and Objectives	2
2 LITERATURE REVIEW	4
2.1 Multiple Myeloma	4
2.1.1 Pathogenesis of Multiple Myeloma	4
2.1.2 Therapeutic Approaches for Multiple Myeloma	7
2.2 Bone Marrow Microenvironment	8
2.2.1 Bone Marrow Microenvironment and Haematopoietic Diseases	10
2.2.2 Bone Marrow Microenvironment and Multiple Myeloma	11
2.2.3 Interleukin-6	12
2.2.4 Mesenchymal Stromal Cells	14
2.3 Targeted Therapy in Multiple Myeloma	15
2.3.1 Monoclonal Antibody Therapy	16
2.3.2 Monoclonal Antibody For Multiple Myeloma Therapy	16
2.3.3 IL-6 Monoclonal Antibody Therapy	17
2.4 RNA Interference	18
2.4.1 RNA Interference Mechanism	18
2.4.2 Therapeutic Application of RNA Interference	20
2.4.3 RNA Interference in Cancer Therapy	22
2.4.4 RNA Interference and Multiple Myeloma	24
3 MATERIALS AND METHODS	26
3.1 Materials	26
3.1.1 Cell Lines	26
3.1.2 Cell Culture Mediums and Reagents	26
3.1.3 Reagents and Chemicals	26
3.1.4 Gel and Ladders	27
3.1.5 Primers, Oligonucleotides and Antibodies	27
3.1.6 Commercial Kits	27
3.1.7 Instrumentation	27
3.1.8 <i>In Vivo</i> Tumour Growth Assay	28

3.1.9	Software and Statistics	28
3.2	Methods	28
3.2.1	Isolation of Bone Marrow MSC	28
3.2.2	Immunophenotype Study	29
3.2.3	Adipogenic Differentiation	29
3.2.4	Osteogenic Differentiation	29
3.2.5	Chondrogenic Differentiation	30
3.2.6	IL-6 Gene Silencing with siRNA by Lipofectamine Transfection	30
3.2.7	Generation of Adenovirus Entry Vector	31
3.2.8	Generation of Adenovirus Expression Vector	31
3.2.9	Production of Adenovirus	31
3.2.10	IL-6 Gene Silencing by Adenoviral Transduction of MSC	32
3.2.11	Viability Assay	32
3.2.12	Analysis of IL-6 mRNA by Real Time PCR	32
3.2.13	Analysis of IL-6 Protein by ELISA	34
3.2.14	<i>In Vitro</i> Viability Assay	34
3.2.15	<i>In Vivo</i> Tumour Growth Assay	35
3.2.16	Histology Analysis	36
4	RESULTS	37
4.1	Isolation and Culture of MSC	37
4.2	Transfection of IL-6 siRNA in MSC	38
4.2.1	Transfection Efficiency	38
4.2.2	IL-6 Suppression in MSC	39
4.2.3	Specificity and Toxicity of siRNA	43
4.3	Transduction of IL-6 shRNA in MSC	47
4.3.1	Design of IL-6 siRNA Sequences	47
4.3.2	Generation of Adenovirus Entry Vector	47
4.3.3	Generation of Adenovirus Expression Vector	50
4.3.4	IL-6 Suppression in MSC	52
4.4	Characterisation of MSC Post RNAi-mediated IL-6 Silencing	54
4.5	<i>In Vitro</i> Viability Assay	59
4.5.1	IL-6 Neutralising Monoclonal Antibody	59
4.5.2	Effect of IL-6 siRNA Transfected MSC on U266 Cell Growth	61
4.5.3	Effect of IL-6 shRNA Transduced MSC on U266 Cell Growth	64
4.6	<i>In Vivo</i> Tumour Growth Assay	68
4.6.1	Effect of U266 Tumour Growth	68
4.6.2	Histology Analysis	70
5	DISCUSSION	74
5.1	RNA Interference for Cancer Therapy	74
5.1.1	RNA Interference via IL-6 siRNA	75
5.1.2	RNA Interference via IL-6 shRNA	77
5.1.3	Comparison of siRNA and shRNA Efficiency	78
5.2	Effect on U266 Cell Growth <i>In Vitro</i>	79
5.2.1	IL-6 siRNA Transfected MSC and U266 Cells	79
5.2.2	IL-6 shRNA Transduced MSC and U266 Cells	80

5.2.3	Efficacy on U266 Cell Growth	80
5.3	Antitumour Efficacy	81
5.4	Limitations in Current Study	84
6	CONCLUSION	87
6.1	Conclusion	87
6.1	Recommendations of Future Research	88
	REFERENCES	90
	APPENDICES	119
	BIODATA OF STUDENT	129
	LIST OF PUBLICATIONS	130



LIST OF TABLES

Table		Page
2.1	Components of the bone marrow microenvironment	9
4.1	Relative quantification of IL-6 mRNA expression of transfected MSC relative to control MSC	42
4.2	siRNA sequences specific to human IL-6	47
4.3	Pathological analysis of U266 tumours co-injected with MSC	71



LIST OF FIGURES

Figure		Page
2.1	Multiple myeloma histology. In multiple myeloma, nuclear pleomorphism such as prominent nucleoli, multinuclearity and abnormal nuclear lobulation are commonly observed.	5
2.2	Pathogenesis of multiple myeloma. The model proposed by Hallek <i>et al.</i> (1998) showed linear progression with specific genetic events occurring in the transformation of normal plasma cells to malignancy.	5
2.3	Pathogenesis of multiple myeloma. The model proposed by Bergsagel and Kuehl (2005) showed three different stages of genetic events in a linear progression driving the transformation of healthy B cells towards malignancy.	6
2.4	Progression of multiple myeloma. Instead of linear progression, it is driven by random accumulations of genetic events with the most adaptable subclone(s) thriving in the bone marrow microenvironment.	7
2.5	Comparisons of enzymatic cascades of endogenous and exogenous RNAi mechanisms.	19
4.1	Morphologies of MSC expanded from bone marrow aspirate.	37
4.2	Transfection efficiency of siRNA into MSC.	38
4.3	IL-6 protein suppression in MSC.	39
4.4	Integrity of extracted total RNA from control and transfected MSC intact with detection of the 28S and 18S bands with the 28S band at roughly twice the intensity of the 18S band.	40
4.5	Plot of log template amount versus Δ CT showed the approximately equal amplification efficiencies of IL-6 and β -actin with slope value < 0.1 .	41
4.6	Real Time PCR showed IL-6 mRNA was suppressed significantly from 72 h post transfection up to 120 h.	41
4.7	Negative siRNA, a non-functional and non-targeting siRNA, when transfected into MSC did not affect the viability compared to control MSC.	43
4.8	Negative siRNA, a non-functional and non-targeting siRNA, when transfected into MSC did not affect the IL-6 expression compared to control MSC.	44

4.9	MSC undergone high degree cell death from 72 h post transfection with the AllStars Hs cell death control siRNA compared control MSC.	45
4.10	Representatives images showing high degree of cell death and cell detachment in MSC post transfection with the AllStars Hs cell death control siRNA beginning from 72 h and persisted through 96 h and 120 h when compared to control MSC.	46
4.11	Top strand of single-stranded oligo was annealed to the bottom strand to generate clearly detectable, double-stranded IL-6 shRNA.	48
4.12	Cloning of double-stranded IL-6 shRNA into TOP10 <i>E.coli</i> produced transformants with amplified adenovirus entry vector cassette (299 bp) from colony PCR.	49
4.13	pAd/BLOCK-iT/IL-6 was digested with Pac1 prior to transfection into 293A cells.	50
4.14	293A cells showed early cytopathic effect by clumping together in clusters by day four post transfection with pAd/BLOCK-iT/IL-6 using Lipofectamine 2000.	51
4.15	Titer for amplified pAd/BLOCK-iT/IL-6 was determined by counting plaque formation in serially diluted viral supernatant.	52
4.16	ELISA assay showed significant suppression of IL-6 protein from 72 h onwards post transduction at MOI 20 and MOI 50.	53
4.17	Ad-U6-RNAi, a non-targeting scrambled shRNA adenovirus expression vector, when transduced into MSC at MOI 20 did not affect the IL-6 protein compared to control MSC.	54
4.18	Luminescent assay showed transfected MSC viability relatively similar to control MSC.	55
4.19	Luminescent assay showed MSC viability unaffected by transduction of pAd/BLOCK-iT/IL-6 when compared to control MSC.	56
4.20	Both IL-6 siRNA transfected MSC and IL-6 shRNA transduced MSC maintained immunophenotypic profile similar to control MSC.	57
4.21	MSC transfected with IL-6 siRNA or transduced with IL-6 shRNA maintained their trilineage differentiation capacity comparable to control MSC.	58
4.22	Significant reduction in IL-6 production was achieved in the supernatant of U266 cells co-cultured directly with MSC and IL-6 neutralising monoclonal antibody.	60

4.23	Significant reduction in IL-6 expression was achieved in the supernatant of U266 cells cultured in MSC conditioned medium with addition of IL-6 neutralising monoclonal antibody.	60
4.24	Significant reduction in cell viability was achieved when U266 cells were co-cultured directly with MSC transfected with IL-6 siRNA.	61
4.25	Significant reduction in IL-6 production was achieved in the supernatant of U266 cells co-cultured directly with MSC transfected with IL-6 siRNA.	62
4.26	For U266 exposed to conditioned medium of MSC transfected with IL-6 siRNA, cell viability also showed significant reduction when compared to U266 exposed to conditioned medium from control MSC.	63
4.27	For U266 exposed to conditioned medium of MSC transfected with IL-6 siRNA, IL-6 production in the supernatant showed significant reduction when compared to U266 exposed to conditioned medium from control MSC.	64
4.28	Significant reduction in cell viability was achieved when U266 cells were co-cultured directly with MSC transduced with IL-6 shRNA by day five.	65
4.29	Significant reduction in IL-6 production was achieved in the supernatant of U266 cells when co-cultured directly with MSC transduced with IL-6 shRNA.	65
4.30	For U266 exposed to conditioned medium of MSC transduced with IL-6 shRNA, cell viability showed significant reduction when compared to U266 exposed to conditioned medium from control MSC.	67
4.31	For U266 exposed to conditioned medium of MSC transduced with IL-6 shRNA, IL-6 production in the supernatant showed significant reduction when compared to U266 exposed to conditioned medium from control MSC.	67
4.32	Mean tumour volume, at day 21, showed significant reduction in tumour co-injected with MSC transfected with IL-6 siRNA and MSC transduced with IL-6 shRNA compared to co-injection with control MSC or MSC with IL-6 neutralising monoclonal antibody added at 60 ng/mL.	69
4.33	Representative images of nude mice and tumours harvested from each group showed reduction of tumours in mice from MSC transfected or transduced with IL-6 shRNA groups compared to control MSC.	69
4.34	Average body weight of mice in groups remained relatively similar suggesting the approaches are well-tolerated.	70

- 4.35 U266 tumours co-injected with control MSC and MSC with IL-6 neutralising monoclonal antibody showed numerous mitotic features than tumours co-injected with MSC transfected with IL-6 siRNA. Tumours with MSC transfected with IL-6 siRNA also showed increased necrosis, lymphocytic infiltrates and presence of fibrosis. 72
- 4.36 U266 tumours co-injected with control MSC and MSC with IL-6 neutralising monoclonal antibody showed numerous mitotic features than tumours co-injected with MSC transduced with IL-6 shRNA. Tumours with MSC transduced with IL-6 shRNA also showed increased lymphocytic infiltrates. 73



LIST OF APPENDICES

Appendix		Page
A	Nucleotide sequences of IL-6 siRNA and DNA oligos	119
B	Research ethics approval	120
C	Sample of patient information sheet and consent form	122
D	Map of pENTR/U6 entry vector	124
E	Map of pAd/BLOCK-iT/DEST vector	125
F	Animal ethics approval	126
G	Blastn results on IL-6 sequence homology	127
H	Blastn results on pENTR/U6/IL-6 entry vector	128



LIST OF ABBREVIATIONS

AAV	Adeno-associated virus
ALL	Acute lymphoblastic leukaemia
ALS	Amyotrophic lateral sclerosis
AML	Acute myeloid leukaemia
ANOVA	Analysis of variance
ApoB	Apolipoprotein B
APRIL	Proliferation-inducing ligand
ASCT	Autologous stem cell transplantation
BP	Base pair
CAM	Cell adhesion mediated
CCD	Charge-coupled device
CCND	Cyclin D
cDNA	Complementary deoxyribonucleic acid
CML	Chronic myeloid leukaemia
c-Myc	v-myc avian myelocytomatosis viral oncogene homolog
CPE	Cytopathic effect
CO ₂	Carbon dioxide
DAPI	4',6-diamidino-2-phenylindole
ddH ₂ O	Double-distilled water
DMEM	Dulbecco's Modified Eagle's Medium
DNA	Deoxyribonucleic acid
D-PBS	Dulbecco's phosphate buffered saline
dsRNA	Double-stranded ribonucleic acid
ECM	Extracellular matrix proteins


EDTA	Ethylenediaminetetraacetic acid
ELISA	Enzyme-linked immunosorbent assay
EMT	Epithelial mesenchymal transition
FBS	Fetal bovine serum
FGFR-3	Fibroblast growth receptor 3
FITC	Fluorescein isothiocyanate
GMP	Good manufacturing practice
HBV	Hepatitis B virus
HGF	Hepatocyte growth factor
HIF-1 α	Hypoxia inducible factor 1 alpha
HIV	Human immunodeficiency virus
HPV	Human papillomavirus
HSC	Haematopoietic stem cells
HTT	Huntingtin
IFN	Interferons
IFN- γ	Interferon gamma
IGF-1	Insulin-like growth factor 1
IL-1 β	Interleukin-1 beta
IL-6	Interleukin-6
IL-8	Interleukin-8
IL-10	Interleukin-10
IL-15	Interleukin-15
IL-17	Interleukin-17
IL-21	Interleukin-21
IL-6R	Interleukin-6 receptor



JAK/STAT	Janus kinase/signal transducer and activator of transcription 3
JNK	c-Jun-NH ₂ -kinase
KB	Kilobase pair
K-Ras	Kirsten-rat sarcoma viral oncogene homolog
LDL	Low-density lipoprotein
mAb	Monoclonal antibody
MAPK	Ras/mitogen-activated protein kinase
MDR1	Multidrug resistance 1
MDS	Myelodysplastic syndrome
MGUS	Monoclonal gammopathy of undetermined significance
miRNA	Micro ribonucleic acid
Mitf	Microphthalmia-associated transcription factor
MLL-AF4	Mixed-lineage leukaemia AF4
MOI	Multiplicity of infection
MPN	Myeloproliferative neoplasms
M-protein	Monoclonal protein
mRNA	Messenger ribonucleic acid
MRP1	Multidrug resistance-associated protein-1
MSC	Mesenchymal stromal cells
MTS	3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)
MTT	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
NF-κB	Nuclear factor kappa-light-chain-enhancer of activated B cells
NK	Natural killer
N-Ras	Neuroblastoma-rat sarcoma viral oncogene homolog
ORR	Overall response rate

p18INK4c	Cyclin-dependent kinase 4 inhibitor 2C
PBMC	Peripheral blood mononuclear cells
PBS	Phosphate buffered saline
PCLS	Poly- ϵ -caprolactone polymeric scaffolds
PCR	Polymerase chain reaction
PCSK9	Proprotein convertase subtilisin/kexin type 9
PD-1	Programmed death 1
PDGF	Platelet-derived growth factor
PD-L1	Programmed death ligand 1
PE	R-phycoerythrin
PFU	Plaquet-forming unit
P-gp	P-glycoprotein 1
PI3K/AKT	Phosphatidylinositol3-kinase/protein kinase B
pre-miRNA	Precursor micro ribonucleic acid
pri-miRNA	Primary micro ribonucleic acid
RANKL	Receptor activator of nuclear factor kappa-B ligand
RB1	Retinoblastoma 1
RISC	RNA-induced silencing complex
RNA	Ribonucleic acid
RNAi	RNA interference
RPMI	Roswell Park Memorial Medium
RRM2	Ribonucleoside-diphosphate reductase subunit M2
RUNX-2	Runt-related transcription factor 2
SCID	Severe combined immunodeficiency
SD	Standard deviation

SDF-1	Stromal-cell derived factor 1
SEM	Standard error of mean
siRNA	Small interfering ribonucleic acid
shRNA	Short hairpin ribonucleic acid
SNP	Single nucleotide polymorphism
SOD1	Superoxide dismutase
T/C	Tumour growth inhibition ratio
TGF- β	Transforming growth factor-beta
TNF- α	Tumour necrosis factor alpha
VEGF	Vascular endothelial growth factor



CHAPTER 1

INTRODUCTION

1.1 Overview

Multiple myeloma is a neoplastic disorder of plasma cells, which accounts for more than 10% of all haematological cancers (Howlader *et al.* 2011). The development of multiple myeloma is a multistep process involving the accumulation of mutations leading to the deregulation of genes controlling cell cycle, apoptosis and the tumour microenvironment interactions. While advances have been made in the treatment and management of multiple myeloma, it remains an incurable disease with an estimated 5-year survival rate of 46.3% (Howlader *et al.* 2011).

Studies have shown that the bone marrow microenvironment plays a crucial role in the pathogenesis of multiple myeloma. The bone marrow microenvironment is composed of extracellular matrix proteins and also a heterogeneous population of haemopoietic and non-haemopoietic cells such as mesenchymal stromal cells (MSC), immune cells and cells involved in osteogenesis. In the case of MSC, *in vitro* studies showed that adhesion of multiple myeloma cells induced the transcription and secretion of cytokines that mediated multiple myeloma cells proliferation and migration (Tosi *et al.* 2006). The cytokines secreted include interleukin-6 (IL-6), insulin-like growth factor 1 (IGF-1) and tumour necrosis factor alpha (TNF- α). IL-6, particularly, is a major growth and survival factor for multiple myeloma cells due to its role in activating specific signal transduction pathways, most notably the Janus kinase/signal transducer and activator of transcription 3 (JAK/STAT) pathway, to induce proliferation and inhibit apoptosis (Ogata *et al.* 1997; Anderson *et al.* 1989; Kawano *et al.* 1988).

MSC in the bone marrow microenvironment promote the growth of multiple myeloma cells mainly by paracrine IL-6 production (Corre *et al.* 2007; Sahara *et al.* 2006) in addition to a positive feedback loop between MSC and myeloma cells that further enhanced stromal production of IL-6 (Roodman 2004; Dankbar *et al.* 2000). In the 1990s, monoclonal antibody (mAb) targeted therapy against IL-6 began using BE-8 murine-derived IL-6 mAb antibody. Findings from phase I studies showed lowered IL-6 level and disease stabilisation but no significant clinical improvements or patient remission (Moreau *et al.* 2000; Bataille *et al.* 1995; Klein *et al.* 1991). A new humanised IL-6 monoclonal antibody, CNTO 328 is currently undergoing clinical trials. Results from two trials on end-stage, progressive multiple myeloma reported disease stabilisation but again no clinically significant responses (van Zaanen *et al.* 1998; van Zaanen *et al.* 1996). However, combination studies on relapsed and refractory multiple myeloma showed early promising results with bortezomib (Voorhees *et al.* 2007), dexamethasone (Voorhees *et al.* 2009) and melphalan (Hunsucker *et al.* 2011).

Targeted IL-6 mAb therapy is hampered by the lack of clinically significant improvements or complete remission for patients with multiple myeloma. New therapeutic approaches are needed to target IL-6 production especially by MSC in order to disrupt the favourable microenvironment that allows the multiple myeloma cells to thrive.

RNA interference (RNAi), which uses double-stranded ribonucleic acid (dsRNA) to selectively silence messenger ribonucleic acid (mRNA) expression, provides a new approach to target overexpression of IL-6 in the development of new multiple myeloma therapy. RNAi can be triggered in mammalian cells by direct administration of small interfering ribonucleic acid (siRNA) or by using vector-based short hairpin ribonucleic acid (shRNA). Chemically synthesised siRNAs are short, non-coding RNAs introduced intracellularly to silence specific genes. As for the vector-based approach, shRNAs are transcribed from external expression vector, exit the nucleus and are cleaved by Dicer to siRNA before induction of RNAi (Yu *et al.* 2002).

RNAi is widely used now as a powerful genetic tool to study mammalian gene function replacing the laborious and costly gene knockout techniques. RNAi is utilised to silence disease-causing genes in the development of targeted therapeutic approaches for human diseases such as genetic disorders (DiFiglia *et al.* 2007; Ding *et al.* 2003), viral diseases (McCaffrey *et al.* 2003; Song *et al.* 2003) and metabolic disorders (Czech *et al.* 2011; Frank-Kamenetsky *et al.* 2008). In addition, RNAi is also used to silence anti-apoptotic, cell cycle and angiogenic genes in different cancer models including liver and prostate (Yano *et al.* 2004), cervical (Yuan *et al.* 2006) and Ewing's sarcoma (Guan *et al.* 2005). RNAi-based clinical trials have also been carried out on solid tumours such as melanoma (Davis *et al.* 2010) and pancreatic adenocarcinoma (Zorde Khvalevsky *et al.* 2013).

Therefore, the hypothesis of this study is RNAi can be utilised for targeted IL-6 silencing in MSC to inhibit growth of multiple myeloma cells. In this study, RNAi-mediated IL-6 silencing was induced in human bone marrow-derived MSC using two different pathways: (1) direct administration of synthetic IL-6 siRNA into MSC using lipofectamine transfection and (2) vector-based adenovirus encoding IL-6 shRNA (pAd/BLOCK-iT/IL-6). The efficacy of these MSC, post RNAi-mediated IL-6 silencing, on inhibition of U266 multiple myeloma cell growth *in vitro* and *in vivo* were subsequently evaluated.

1.2 Aims and Objectives

The main aim of this study is to investigate the efficacy of RNAi-mediated silencing of IL-6 in human bone marrow-derived MSC on the growth of U266 multiple myeloma cells *in vitro* and *in vivo*. The specific objectives of this study are as follows:

1. To isolate, culture and characterise MSC from bone marrow aspirate of apparently healthy individuals.
2. To induce IL-6 silencing in MSC using synthetic IL-6 siRNA and vector-based recombinant adenovirus encoding IL-6 shRNA.
3. To investigate the viability, immunophenotypic profile and trilineage differentiation capacity of the above MSC post RNAi-mediated IL-6 silencing.
4. To investigate inhibition of U266 cell growth after co-culture with MSC post RNAi-mediated IL-6 silencing MSC *in vitro*.
5. To investigate antitumour efficacy of MSC post RNAi-mediated IL-6 silencing in a murine subcutaneous model of human multiple myeloma.



REFERENCES

- Aagaard, L., & Rossi, J. J. (2007). RNAi therapeutics: Principles, prospects and challenges. *Adv. Drug Deliv. Rev.* **59**(2-3): 75-86.
- Adams, J. C., & Watt, F. M. (1993). Regulation of development and differentiation by the extracellular matrix. *Development* **117**(4): 1183-1198.
- Ahn, M., Witting, S. R., Ruiz, R., Saxena, R., & Morral, N. (2011). Constitutive expression of shRNA *in vivo* triggers build up of mature hairpin molecules. *Hum. Gene Ther.* **22**(12): 1483-1497.
- Alexandrakis, M. G., Passam, F. H., Kyriakou, D. S., Dambaki, K., Niniraki, M., & Stathopoulos, E. (2004). Ki-67 proliferation index: Correlation with prognostic parameters and outcome in multiple myeloma. *Am. J. Clin. Oncol.* **27**(1): 8-13.
- Allay, J. A., Dennis, J. E., Haynesworth, S. E., Majumdar, M. K., Clapp, D. W., Shultz, L. D., Caplan, A. I., & Gerson, S. L. (1997). LacZ and interleukin-3 expression *in vivo* after retroviral transduction of marrow-derived human osteogenic mesenchymal progenitors. *Hum. Gene Ther.* **8**(12): 1417-1427.
- Altieri, D. C. (2003). Survivin, versatile modulation of cell division and apoptosis in cancer. *Oncogene* **22**(53): 8581-8589.
- Anderson, K. C., Jones, R. M., Morimoto, C., Leavitt, P., & Barut, B. A. (1989). Response patterns of purified myeloma cells to hematopoietic growth factors. *Blood* **73**(7): 1915-1924.
- Angtuaco, E. J., Fassas, A. B., Walker, R., Sethi, R., & Barlogie, B. (2004). Multiple myeloma: Clinical review and diagnostic imaging. *Radiology* **231**(1): 11-23.
- Argyriou, A. A., Iconomou, G., & Kalofonos, H. P. (2008). Bortezomib-induced peripheral neuropathy in multiple myeloma: A comprehensive review of the literature. *Blood* **112**(5): 1593-1599.
- Askmyr, M., Quach, J., & Purton, L. E. (2011). Effects of the bone marrow microenvironment on hematopoietic malignancy. *Bone* **48**(1): 115-120.
- Atanackovic, D., Luetkens, T., & Kroger, N. (2014). Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. *Leukemia* **28**(5): 993-1000.
- Attal, M., Harousseau, J. L., Stoppa, A. M., Sotto, J. J., Fuzibet, J. G., Rossi, J. F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C., & Bataille, R. (1996). A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. *N. Engl. J. Med.* **335**(2): 91-97.
- Azab, A. K., Runnels, J. M., Pitsillides, C., Moreau, A. S., Azab, F., Leleu, X., X., J., Wright, R., Ospina, B., Carlson, A. L., Alt, C., Burwick, N., Roccaro, A. M.,

- Ngo, H. T., Faraq, M., Melhem, M. R., Sacco, A., Munshi, N. C., Hideshima, T., Rollins, B. J., Anderson, K. C., Kung, A. L., Lin, C. P., & Ghobrial, I. M. (2009). CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. *Blood* **113**(18): 4341-4351.
- Bahlis, N. J. (2012). Darwinian evolution and tiding clones in multiple myeloma. *Blood* **120**(5): 927-928.
- Barabe, F., Kennedy, J. A., Hope, K. J., & Dick, J. E. (2007). Modeling the initiation and progression of human acute leukemia in mice. *Science* **316**(5824): 600-604.
- Barille, S., Collette, M., Bataille, R., & Amiot, M. (1995). Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin. *Blood* **86**(8): 3151-3159.
- Barlogie, B., Shaughnessy, J., Tricot, G., Jacobson, J., Zangari, M., Anaissie, E., Walker, R., & Crowley, J. (2004). Treatment of multiple myeloma. *Blood* **103**(1): 20-32.
- Bartel, D. P. (2004). MicroRNAs: Genomics, biogenesis, mechanism, and function. *Cell* **116**(2): 281-297.
- Bataille, R., Barlogie, B., Lu, Z. Y., Rossi, J. F., Lavabre-Bertrand, T., Beck, T., Wijdenes, J., Brochier, J., & Klein, B. (1995). Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. *Blood* **86**(2): 685-691.
- Bataille, R., & Harousseau, J. L. (1997). Multiple myeloma. *N. Engl. J. Med.* **336**(23): 1657-1664.
- Beckman, R. A., Weiner, L. M., & Davis, H. M. (2007). Antibody constructs in cancer therapy: Protein engineering strategies to improve exposure in solid tumors. *Cancer* **109**(2): 170-179.
- Bello, C., & Sotomayor, E. M. (2007). Monoclonal antibodies for B-cell lymphomas: Rituximab and beyond. *Hematology Am. Soc. Hematol. Educ. Program*: 233-242.
- Benoit, D. S. W., & Boutin, M. E. (2012). Controlling mesenchymal stem cell gene expression using polymer-mediated delivery of siRNA. *Biomacromolecules* **13**(11): 3841-3849.
- Berenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M., Blacklock, H., Bell, R., Simeone, J. F., Reitsma, D. J., Heffernan, M., Seaman, J., & Knight, R. D. (1998). Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. *J. Clin. Oncol.* **16**(2): 593-602.

- Berenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M. J., Blacklock, H. A., Bell, R., Simeone, J., Reitsma, D. J., Heffernan, M., Seaman, J., & Knight, R. D. (1996). Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. *N. Engl. J. Med.* **334**(8): 488-493.
- Bergfeld, S. A., & DeClerck, Y. A. (2010). Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. *Cancer Metastasis Rev.* **29**(2): 249-261.
- Bergsagel, P. L., & Kuehl, W. M. (2005). Molecular pathogenesis and a consequent classification of multiple myeloma. *J. Clin. Oncol.* **23**(26): 6333-6338.
- Betts, B. C., St Angelo, E. T., Kennedy, M., & Young, J. W. (2011). Anti-IL6-receptor-alpha (tocilizumab) does not inhibit human monocyte-derived dendritic cell maturation or alloreactive T-cell responses. *Blood* **118**(19): 5340-5343.
- Bloem, A. C., Lamme, T., de Smet, M., Kok, H., Vooijs, W., Wijdenes, J., Boom, S. E., & Lokhorst, H. M. (1998). Long term bone marrow cultured stroma cells regulate myeloma tumour growth *in vitro*: Studies with primary tumour cells and LTBMCC-dependent cell lines. *Br. J. Haemato.* **100**(1): 166-175.
- Bonab, M. M., Alimoghaddam, K., Talebian, F., Ghaffari, S. H., Ghavamzadeh, A., & Nikbin, B. (2006). Aging of mesenchymal stem cell *in vitro*. *BMC Cell Biol* **7**: 14.
- Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., Ove, R., Kies, M. S., Baselga, J., Youssoufian, H., Amellal, N., Rowinsky, E. K., & Ang, K. K. (2006). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. *N. Engl. J. Med.* **354**(6): 567-578.
- Boudreau, R. L., Monteys, A. M., & Davidson, B. L. (2008). Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs. *RNA* **14**(9): 1834-1844.
- Boudreau, R. L., Spengler, R. M., & Davidson, B. L. (2011). Rational design of therapeutic siRNAs: Minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease. *Mol. Ther.* **19**(12): 2169-2177.
- Brenne, A. T., Ro, T. B., Waage, A., Sundan, A., Borset, M., & Hjorth-Hansen, H. (2002). Interleukin-21 is a growth and survival factor for human myeloma cells. *Blood* **99**(10): 3756-3762.
- Bridge, A. J., Pebernard, S., Ducraux, A., Nicoulaz, A. L., & Iggo, R. (2003). Induction of an interferon response by RNAi vectors in mammalian cells. *Nat. Genet.* **34**(3): 263-264.

- Brioli, A., Melchor, L., Walker, B. A., Davies, F. E., & Morgan, G. J. (2014). Biology and treatment of myeloma. *Clin. Lymphoma Myeloma Leuk.* **14S**: S65-S70.
- Brummelkamp, T. R., Bernards, R., & Agami, R. (2002). A system for stable expression of short interfering RNAs in mammalian cells. *Science* **296**(5567): 550-553.
- Burger, R., Guenther, A., Bakker, F., Schmalzing, M., Bernand, S., Baum, W., Duerr, B., Hocke, G. M., Steininger, H., Gebhart, E., & Gramatzki, M. (2001). Gp130 and ras mediated signaling in human plasma cell line INA-6: A cytokine-regulated tumor model for plasmacytoma. *Hematol. J.* **2**(1): 42-53.
- Caffrey, D. R., Zhao, J., Song, Z., Schaffer, M. E., Haney, S. A., Subramaniam, R. R., A.B., S., & Hughes, J. D. (2011). siRNA off-target effects can be reduced at concentrations that match their individual potency. *PLoS One* **6**(7): e21503.
- Caldas, H., Holloway, M. P., Hall, B. M., Qualman, S. J., & Altura, R. A. (2006). Survivin-directed RNA interference cocktail is a potent suppressor of tumour growth *in vivo*. *J. Med. Genet.* **43**(2): 119-128.
- Calimeri, T., Battista, E., Conforti, F., Neri, P., Di Martino, M. T., Rossi, M., Foresta, U., Piro, E., Ferrara, F., Amorosi, A., Bahlis, N., Anderson, K. C., Munshi, N., Tagliaferri, P., Causa, F., & Tassone, P. (2011). A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for *in vivo* expansion of human primary multiple myeloma cells. *Leukemia* **25**(4): 707-711.
- Campochiaro, P. A. (2006). Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders. *Gene Ther.* **13**(6): 559-562.
- Chames, P., Van Regenmortel, M., Weiss, E., & Baty, D. (2009). Therapeutic antibodies: Successes, limitations and hopes for the future. *Br. J. Pharmacol.* **157**(2): 220-233.
- Chang, J. H., Garg, N. K., Lunde, E., Han, K. Y., Jain, S., & Azar, D. T. (2012). Corneal neovascularization: An anti-VEGF therapy review. *Surv. Ophthalmol.* **57**(5): 415-429.
- Chauhan, D., Pandey, P., Hideshima, T., Treon, S., Raje, N., Davies, F. E., Shima, Y., Tai, Y. T., Rosen, S., Avraham, S., Kharbanda, S., & Anderson, K. C. (2000). SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. *J. Biol. Chem.* **275**(36): 27845-27850.
- Chauhan, D., Uchiyama, H., Akbarali, Y., Urashima, M., Yamamoto, K., Libermann, T. A., & Anderson, K. C. (1996). Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. *Blood* **87**(3): 1104-1112.

- Chen, J., Yang, L., Chen, H., Yuan, T., Liu, M., & Chen, P. (2014a). Recombinant adenovirus encoding FAT10 small interfering RNA inhibits HCC growth *in vitro* and *in vivo*. *Exp. Mol. Pathol.* **96**(2): 207-211.
- Chen, Q. X., Song, S. W., Chen, Q. H., Zeng, C. L., Zheng, X., Wang, J. L., & Fang, X. M. (2014b). Silencing airway epithelial cell-derived hepcidin exacerbates sepsis induced acute lung injury. *Crit. Care* **18**(4): 470.
- Chen, Y., Bathula, S. R., Li, J., & Huang, L. (2010). Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. *J. Biol. Chem.* **285**(29): 22639-22650.
- Cheng, J., Li, L., Liu, Y., Wang, Z., Zhu, X., & Bai, X. (2012). Interleukin-1 alpha induces immunosuppression by mesenchymal stem cells promoting the growth of prostate cancer cells. *Mol. Med. Rep.* **6**(5): 955-960.
- Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003). High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. *N. Engl. J. Med.* **348**(19): 1875-1883.
- Chuah, M. K., Van Damme, A., Zwinnen, H., Goovaerts, I., Vanslembrouck, V., Collen, D., & Vanden Driessche, T. (2000). Long-term persistence of human bone marrow stromal cells transduced with factor VIII-retroviral vectors and transient production of therapeutic levels of human factor VIII in nonmyeloablated immunodeficient mice. *Hum. Gene Ther.* **11**(5): 729-738.
- Clemente, C. G., Mihm, M. C., Jr., Bufalino, R., Zurrida, S., Collini, P., & Cascinelli, N. (1996). Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. *Cancer* **77**(7): 1303-1310.
- Cocks, B. G., & Theriault, T. P. (2004). Developments in effective application of small inhibitory RNA (siRNA) technology in mammalian cells. *DDT: Targets* **3**(4): 165-171.
- Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P., & Gisselbrecht, C. (2002). CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. *N. Engl. J. Med.* **346**(4): 235-242.
- Corre, J., Mahtouk, K., Attal, M., Gadelorge, M., Huynh, A., Fleury-Cappellesso, S., Danho, C., Laharrague, P., Klein, B., Reme, T., & Bourin, P. (2007). Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. *Leukemia* **21**(5): 1079-1088.
- Culig, Z. (2011). Cytokine disbalance in common human cancers. *Biochim. Biophys. Acta* **1813**(2): 308-314.
- Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., Chau, I., & Van Cutsem, E.

- (2004). Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. *N. Engl. J. Med.* **351**(4): 337-345.
- Czech, M. P., Aouadi, M., & Tesz, G. J. (2011). RNAi-based therapeutic strategies for metabolic disease. *Nat. Rev. Endocrinol.* **7**(8): 473-484.
- Dankbar, B., Padro, T., Leo, R., Feldmann, B., Kropff, M., Mesters, R. M., Serve, H., Berdel, W. E., & Kienast, J. (2000). Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. *Blood* **95**(8): 2630-2636.
- Davis, M. E., Zuckerman, J. E., Choi, C. H., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010). Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. *Nature* **464**(7291): 1067-1070.
- de Weers, M., Tai, Y. T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., Mutis, T., Bleeker, W. K., Anderson, K. C., Lokhorst, H. M., van de Winkel, J. G., & Parren, P. W. (2011). Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. *J. Immunol.* **186**(3): 1840-1848.
- Deng, Y., Wang, C. C., Choy, K. W., Du, Q., Chen, J., Wang, Q., Li, L., Chung, T. K., & Tang, T. (2014). Therapeutic potentials of gene silencing by RNA interference: Principles, challenges, and new strategies. *Gene* **538**(2): 217-227.
- Dhodapkar, M. V., Kelly, T., Theus, A., Athota, A. B., Barlogie, B., & Sanderson, R. D. (1997). Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma. *Br. J. Haematol.* **99**(2): 368-371.
- Diamant, M., Hansen, M. B., Rieneck, K., Svenson, M., Yasukawa, K., & Bendtzen, K. (1996). Differential interleukin-6 (IL-6) responses of three established myeloma cell lines in the presence of soluble human IL-6 receptors. *Leuk Res* **20**(4): 291-301.
- DiFiglia, M., Sena-Esteves, M., Chase, K., Sapp, E., Pfister, E., Sass, M., Yoder, J., Reeves, P., Pandey, R. K., Rajeev, K. G., Manoharan, M., Sah, D. W., Zamore, P. D., & Aronin, N. (2007). Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. *Proc. Natl. Acad. Sci. USA* **104**(43): 17204-17209.
- Ding, H., Schwarz, D. S., Keene, A., Affar el, B., Fenton, L., Xia, X., Shi, Y., Zamore, P. D., & Xu, Z. (2003). Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis. *Aging Cell* **2**(4): 209-217.
- Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D., Deans, R., Keating, A., Prockop, D., & Horwitz, E. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* **8**(4): 315-317.

- Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001a). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. *Nature* **411**(6836): 494-498.
- Elbashir, S. M., Lendeckel, W., & Tuschl, T. (2001b). RNA interference is mediated by 21- and 22-nucleotide RNAs. *Genes Dev.* **15**(2): 188-200.
- Esteve, F. R., & Roodman, G. D. (2007). Pathophysiology of myeloma bone disease. *Best Pract. Res. Clin. Haematol.* **20**(4): 613-624.
- Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998). Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans*. *Nature* **391**(6669): 806-811.
- Flores-Figueroa, E., Gutierrez-Espindola, G., Montesinos, J. J., Arana-Trejo, R. M., & Mayani, H. (2002). *In vitro* characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome. *Leuk. Res.* **26**(7): 677-686.
- Frank-Kamenetsky, M., Grefhorst, A., Anderson, N. N., Racie, T. S., Bramlage, B., Akinc, A., Butler, D., Charisse, K., Dorkin, R., Fan, Y., Gamba-Vitalo, C., Hadwiger, P., Jayaraman, M., John, M., Jayaprakash, K. N., Maier, M., Nechev, L., Rajeev, K. G., Read, T., Rohl, I., Soutschek, J., Tan, P., Wong, J., Wang, G., Zimmermann, T., de Fougerolles, A., Vornlocher, H. P., Langer, R., Anderson, D. G., Manoharan, M., Kotliansky, V., Horton, J. D., & Fitzgerald, K. (2008). Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. *Proc. Natl. Acad. Sci. USA* **105**(33): 11915-11920.
- Freeley, M., & Long, A. (2013). The two hit hypothesis: An improved method for siRNA-mediated gene silencing in stimulated primary human T cells. *J. Immunol. Methods* **396**(1-2): 116-127.
- Freneaux, P., Stoppa-Lyonnet, D., Mouret, E., Kambouchner, M., Nicolas, A., Zafrani, B., Vincent-Salomon, A., Fourquet, A., Magdelenat, H., & Sastre-Garau, X. (2000). Low expression of bcl-2 in Brca1-associated breast cancers. *Br. J. Cancer* **83**(10): 1318-1322.
- Fu, G. F., Lin, X. H., Han, Q. W., Fan, Y. R., Xu, Y. F., Guo, D., Xu, G. X., & Hou, Y. Y. (2005). RNA interference remarkably suppresses bcl-2 gene expression in cancer cells *in vitro* and *in vivo*. *Cancer Biol. Ther.* **4**(8): 822-829.
- Fulciniti, M., Hideshima, T., Vermot-Desroches, C., Pozzi, S., Nanjappa, P., Shen, Z. X., Pate, I. N., Smith, E. S., Prabhala, R., Tai, Y. Z., Tassone, P., Anderson, K. C., & Munshi, N. C. (2009). A high-affinity fully human anti-IL-6 mAb (OP-R003-1, 1339) for the treatment of multiple myeloma. *Clin. Cancer Res.* **15**(23): 7144-7152.
- Gao, K., & Huang, L. (2013). Achieving efficient RNAi therapy: Progress and challenges. *Acta Pharm. Sin. B.* **3**(4): 213-225.

- Gedmintas, L., Solomon, D. H., & Kim, S. C. (2013). Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: A systematic review and meta-analysis. *J. Bone Miner. Res.* **28**(8): 1729-1737.
- Ghia, P., Granziero, L., Chilosi, M., & Caligaris-Cappio, F. (2002). Chronic B cell malignancies and bone marrow microenvironment. *Semin. Cancer Biol.* **12**(2): 149-155.
- Gilmore, I. R., Fox, S. P., Hollins, A. J., Sohail, M., & Akhtar, S. (2004). The design and exogenous delivery of siRNA for post-transcriptional gene silencing. *J. Drug Target* **12**(6): 315-340.
- Giuliani, N., Bataille, R., Mancini, C., Lazzaretti, M., & Barille, S. (2001). Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. *Blood* **98**(13): 3527-3533.
- Gojo, S., Gojo, N., Takeda, Y., Mori, T., Abe, H., Kyo, S., Hata, J., & Umezawa, A. (2003). *In vivo* cardiovascularogenesis by direct injection of isolated adult mesenchymal stem cells. *Exp. Cell Res.* **288**(1): 51-59.
- Graham, F. L., Harrison, T., & Williams, J. (1978). Defective transforming capacity of adenovirus type 5 host-range mutants. *Virology* **86**(1): 10-21.
- Graham, F. L., Smiley, J., Russell, W. C., & Nairn, R. (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. *J Gen Virol* **36**(1): 59-74.
- Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A. (2006). Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. *Nature* **441**(7092): 537-541.
- Guan, H., Zhou, Z., Wang, H., Jia, S. F., Liu, W., & Kleinerman, E. S. (2005). A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model. *Clin. Cancer Res.* **11**(7): 2662-2669.
- Guidoboni, M., Gafa, R., Viel, A., Doglioni, C., Russo, A., Santini, A., Del Tin, L., Macri, E., Lanza, G., Boiocchi, M., & Dolcetti, R. (2001). Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with favourable prognosis. *Am. J. Pathol.* **159**(1): 297-304.
- Gunn, W. G., Conley, A., Deininger, L., Olson, S. D., Prockop, D. J., & Gregory, C. A. (2006). A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: A potential role in the development of lytic bone disease and tumour progression in multiple myeloma. *Stem Cells* **24**(4): 986-991.
- Guo, W., Chen, W., Yu, W., Huang, W., & Deng, W. (2013). Small interfering RNA-based molecular therapy of cancers. *Chin. J. Cancer* **32**(9): 488-493.

- Hallek, M., Bergsagel, P. L., & Anderson, K. C. (1998). Multiple myeloma: Increasing evidence for a multistep transformation process. *Blood* **91**(1): 3-21.
- Hamilton, A. J., & Baulcombe, D. C. (1999). A species of small antisense RNA in posttranscriptional gene silencing in plants. *Science* **286**(5441): 950-952.
- Han, Z., Tian, Z., Lv, G., Zhang, L., Jiang, G., Sun, K., Wang, C., Bu, X., Li, R., Shi, Y., Wu, M., & Wei, L. (2011). Immunosuppressive effect of bone marrow-derived mesenchymal stem cells in inflammatory microenvironment favours the growth of B16 melanoma cells. *J. Cell Mol. Med.* **15**(11): 2343-2352.
- Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. *Cell* **100**(1): 57-70.
- Harper, S. Q., Staber, P. D., He, X., Eliason, S. L., Martins, I. H., Mao, Q., Yang, L., Kotin, R. M., Paulson, H. L., & Davidson, B. L. (2005). RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. *Proc. Natl. Acad. Sci. USA* **102**(16): 5820-5825.
- Heinrich, P. C., Behrmann, I., Muller-Newen, G., Schaper, F., & Graeve, L. (1998). Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. *Biochem. J.* **334** (Pt 2): 297-314.
- Hideshima, T., & Anderson, K. C. (2002). Molecular mechanisms of novel therapeutic approaches for multiple myeloma. *Nat. Rev. Cancer* **2**(12): 927-937.
- Hideshima, T., Catley, L., Yasui, H., Ishitsuka, K., Raje, N., Mitsiades, C., Podar, K., Munshi, N. C., Chauhan, D., Richardson, P. G., & Anderson, K. C. (2006). Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces *in vitro* and *in vivo* cytotoxicity in human multiple myeloma cells. *Blood* **107**(10): 4053-4062.
- Hideshima, T., Chauhan, D., Schlossman, R., Richardson, P., & Anderson, K. C. (2001a). The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: Therapeutic applications. *Oncogene* **20**(33): 4519-4527.
- Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F. E., Tai, Y. T., Treon, S. P., Lin, B., Schlossman, R. L., Richardson, P., Muller, G., Stirling, D. I., & Anderson, K. C. (2000). Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. *Blood* **96**(9): 2943-2950.
- Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007). Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. *Nat. Rev. Cancer* **7**(8): 585-598.
- Hideshima, T., Nakamura, N., Chauhan, D., & Anderson, K. C. (2001b). Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. *Oncogene* **20**(42): 5991-6000.

- Hideshima, T., Richardson, P., Chauhan, D., Palombella, V. J., Elliott, P. J., Adams, J., & Anderson, K. C. (2001c). The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. *Cancer Res.* **61**(7): 3071-3076.
- Hilbert, D. M., Kopf, M., Mock, B. A., Kohler, G., & Rudikoff, S. (1995). Interleukin 6 is essential for *in vivo* development of B lineage neoplasms. *J. Exp. Med.* **182**(1): 243-248.
- Holen, T., Amarzguioui, M., Wiiger, M. T., Babaie, E., & Prydz, H. (2002). Positional effects of short interfering RNAs targeting the human coagulation trigger tissue factor. *Nucleic Acids Res.* **30**(8): 1757-1766.
- Howlader, N., Noone, A. M., Krapcho, M., Garshell, J., Miller, D., Altekruse, S. F., Kosary, C. L., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., Lewis, D. R., Chen, H. S., Feuer, E. J., & Cronin, K. A. (2011). SEER cancer statistics review, 1975-2011, National Cancer Institute. Bethesda, MD. Retrieved 29/12/2014, 2014 from http://seer.cancer.gov/csr/1975_2011/.
- Hsi, E. D., Steinle, R., Balasa, B., Szmania, S., Draksharapu, A., Shum, B. P., Huseni, M., Powers, D., Nanisetti, A., Zhang, Y., Rice, A. G., van Abbema, A., Wong, M., Liu, G., Zhan, F., Dillon, M., Chen, S., Rhodes, S., Fuh, F., Tsurushita, N., Kumar, S., Vexler, V., Shaughnessy, J. D., Jr., Barlogie, B., van Rhee, F., Hussein, M., Afar, D. E., & Williams, M. B. (2008). CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. *Clin. Cancer Res.* **14**(9): 2775-2784.
- Hsu, H. S., Lin, J. H., Hsu, T. W., Su, K., Wang, C. W., Yang, K. Y., Chiou, S. H., & Hung, S. C. (2012). Mesenchymal stem cells enhance lung cancer initiation through activation of IL-6/JAK2/STAT3 pathway. *Lung Cancer* **75**(2): 167-177.
- Hu, Y., Kirito, K., Yoshida, K., Mitsumori, T., Nakajima, K., Nozaki, Y., Hamanaka, S., Nagashima, T., Kunitama, M., Sakoe, K., & Komatsu, N. (2009). Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan. *Mol. Cancer Ther.* **8**(8): 2329-2338.
- Hua, J., Mutch, D. G., & Herzog, T. J. (2005). Stable suppression of MDR-1 gene using siRNA expression vector to reverse drug resistance in a human uterine sarcoma cell line. *Gynecol. Oncol.* **98**(1): 31-38.
- Hunsucker, S. A., Magarotto, V., Kuhn, D. J., Kornblau, S. M., Wang, M., Weber, D. M., Thomas, S. K., Shah, J. J., Voorhees, P. M., Xie, H., Cornfeld, M., Nemeth, J. A., & Orłowski, R. Z. (2011). Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. *Br. J. Haematol.* **152**(5): 579-592.
- Huppi, K., Martin, S. E., & Caplen, N. J. (2005). Defining and assaying RNAi in mammalian cells. *Mol. Cell* **17**(1): 1-10.
- Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G.,

- Rogers, B., Ross, R., & Kabbinavar, F. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N. Engl. J. Med.* **350**(23): 2335-2342.
- Ikeda, H., Hideshima, T., Fulciniti, M., Perrone, G., Miura, N., Yasui, H., Okawa, Y., Kiziltepe, T., Santo, L., Vallet, S., Cristea, D., Calabrese, E., Gorgun, G., Raje, N. S., Richardson, P., Munshi, N. C., Lannutti, B. J., Puri, K. D., Giese, N. A., & Anderson, K. C. (2010). PI3K/p110 $\{\delta\}$ is a novel therapeutic target in multiple myeloma. *Blood* **116**(9): 1460-1468.
- Jacque, J. M., Triques, K., & Stevenson, M. (2002). Modulation of HIV-1 replication by RNA interference. *Nature* **418**(6896): 435-438.
- Jakubowiak, A. J., Benson, D. M., Bensinger, W., Siegel, D. S., Zimmerman, T. M., Mohrbacher, A., Richardson, P. G., Afar, D. E., Singhal, A. K., & Anderson, K. C. (2012). Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. *J. Clin. Oncol.* **30**(16): 1960-1965.
- Jia, F., Zhang, Y. Z., & Liu, C. M. (2007). Stable inhibition of hepatitis B virus expression and replication in HepG2.2.15 cells by RNA interference based on retrovirus delivery. *J. Biotechnol.* **128**(1): 32-40.
- Jiang, M., & Milner, J. (2002). Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. *Oncogene* **21**(39): 6041-6048.
- Jing, Y., Han, Z., Liu, Y., Sun, K., Zhang, S., Jiang, G., Li, R., Gao, L., Zhao, X., Wu, D., Cai, X., Wu, M., & Wei, L. (2012). Mesenchymal stem cells in inflammation microenvironment accelerates hepatocellular carcinoma metastasis by inducing epithelial-mesenchymal transition. *PLoS One* **7**(8): e43272.
- John, B., Enright, A. J., Aravin, A., Tuschl, T., Sander, C., & Marks, D. S. (2004). Human microRNA targets. *PLoS Biol.* **2**(11): e363.
- Judge, A. D., Sood, V., Shaw, J. R., Fang, D., McClintok, K., & MacLachlan, I. (2005). Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNAs. *Nat. Biotech.* **23**(4): 457-462.
- Kapoor, P., Greipp, P. T., Morice, W. G., Rajkumar, S. V., Witzig, T. E., & Greipp, P. R. (2008). Anti-CD20 monoclonal antibody therapy in multiple myeloma. *Br. J. Haematol.* **141**(2): 135-148.
- Kariko, K., Bhuyan, P., Capodici, J., Ni, H., Lubinski, J., Friedman, H., & Weissman, D. (2004). Exogenous siRNA mediates sequence-independent gene suppression by signalling through toll-like receptor 3. *Cells Tissues Organs* **177**(3): 132-138.
- Katz, B. Z. (2010). Adhesion molecules: The lifelines of multiple myeloma cells. *Semin. Cancer Biol.* **20**(3): 186-195.

- Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., Kuramoto, A., & Kishimoto, T. (1988). Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. *Nature* **332**(6159): 83-85.
- Keats, J. J., Chesi, M., Egan, J. B., Garbitt, V. M., Palmer, S. E., Braggio, E., Van Wier, S., Blackburn, P. R., Baker, A. S., Dispenzieri, A., Kumar, S., Rajkumar, S. V., Carpten, J. D., Barrett, M., Fonseca, R., Stewart, A. K., & Bergsagel, P. L. (2012). Clonal competition with alternating dominance in multiple myeloma. *Blood* **120**(5): 1067-1076.
- Keller, E. T., & Ershler, W. B. (1995). Effect of IL-6 receptor antisense oligodeoxynucleotide on *in vitro* proliferation of myeloma cells. *J. Immunol.* **154**(8): 4091-4098.
- Kenworthy, R., Lambert, D., Yang, F., Wang, N., Chen, Z., Zhu, H., Liu, C., Li, K., & Tang, H. (2009). Short-hairpin RNAs delivered by lentiviral vector transduction trigger RIG-1-mediated IFN activation. *Nucleic Acids Res.* **37**(19): 6587-6599.
- Klein, B. (1995). Cytokine, cytokine receptors, transduction signals, and oncogenes in human multiple myeloma. *Semin. Hematol.* **32**(1): 4-19.
- Klein, B., Seckinger, A., Moehler, T., & Hose, D. (2011). Molecular pathogenesis of multiple myeloma: Chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment. *Recent Results Cancer Res.* **183**: 39-86.
- Klein, B., Wijdenes, J., Zhang, X. G., Jourdan, M., Boiron, J. M., Brochier, J., Liautard, J., Merlin, M., Clement, C., & Morel-Fournier, B. (1991). Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. *Blood* **78**(5): 1198-1204.
- Klein, B., Zhang, X. G., Jourdan, M., Boiron, J. M., Portier, M., Lu, Z. Y., Wijdenes, J., Brochier, J., & Bataille, R. (1990). Interleukin-6 is the central tumor growth factor *in vitro* and *in vivo* in multiple myeloma. *Eur. Cytokine Netw.* **1**(4): 193-201.
- Klein, B., Zhang, X. G., Jourdan, M., Content, J., Houssiau, F., Aarden, L., Piechaczyk, M., & Bataille, R. (1989). Paracrine rather than autocrine regulation of myeloma cell growth and differentiation by interleukin-6. *Blood* **73**(2): 517-526.
- Kopp, H. G., Avecilla, S. T., Hooper, A. T., & Rafii, S. (2005). The bone marrow vascular niche: Home of HSC differentiation and mobilization. *Physiology* **20**: 349-356.
- Kozarsky, K. F., & Wilson, J. M. (1993). Gene therapy: Adenovirus vectors. *Curr. Opin. Genet. Dev.* **3**: 499-503.

- Krougliak, K. F., & Graham, F. L. (1995). Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants. *Hum. Gene Ther.* **6**: 1575-1586.
- Kubo, K., Tomita, K., Uto, A., Kuroda, K., Seshadri, S., Cohen, J., Kaibuchi, K., Kamiya, A., & Nakajima, K. (2010). Migration defects by DISC1 knockdown in C57BL/6, 129X1/SvJ, and ICR strains via *in utero* gene transfer and virus-mediated RNAi. *Biochem. Biophys. Res. Commun.* **400**(4): 631-637.
- Kuehl, W. M., & Bergsagel, P. L. (2002). Multiple myeloma: Evolving genetic events and host interactions. *Nat. Rev. Cancer* **2**(3): 175-187.
- Kuehl, W. M., & Bergsagel, P. L. (2012). Molecular pathogenesis of multiple myeloma and its premalignant precursor. *J. Clin. Invest.* **122**(10): 3456-3463.
- Kuhn, D. J., Berkova, Z., Jones, R. J., Woessner, R., Bjorklund, C. C., Ma, W., Davis, R. E., Lin, P., Wang, H., Madden, T. L., Wei, C., Baladandayuthapani, V., Wang, M., Thomas, S. K., Shah, J. J., Weber, D. M., & Orlowski, R. Z. (2012). Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. *Blood* **120**(16): 3260-3270.
- Kyle, R. A., & Rajkumar, S. V. (2009a). Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. *Leukemia* **23**(1): 3-9.
- Kyle, R. A., & Rajkumar, S. V. (2009b). Treatment of multiple myeloma: A comprehensive review. *Clin. Lymphoma Myeloma* **9**(4): 278-288.
- Lacy, M. Q., Dispenzieri, A., Gertz, M. A., Greipp, P. R., Gollbach, K. L., Hayman, S. R., Kumar, S., Lust, J. A., Rajkumar, S. V., Russell, S. J., Witzig, T. E., Zeldenrust, S. R., Dingli, D., Bergsagel, P. L., Fonseca, R., Reeder, C. B., Stewart, A. K., Roy, V., Dalton, R. J., Carr, A. B., Kademani, D., Keller, E. E., Viozzi, C. F., & Kyle, R. A. (2006). Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. *Mayo Clin. Proc.* **81**(8): 1047-1053.
- Landry, B., Aliabadi, H. M., Samuel, A., Gul-Uludag, H., Jiang, X., Kutsch, O., & Uludag, H. (2012). Effective non-viral delivery of siRNA to acute myeloid leukemia cells with lipid-substituted polyethylenimines. *PLoS One* **7**(8): e44197.
- Le Gouill, S., Podar, K., Amiot, M., Hideshima, T., Chauhan, D., Ishitsuka, K., Kumar, S., Raje, N., Richardson, P. G., Harousseau, J. L., & Anderson, K. C. (2004). VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. *Blood* **104**(9): 2886-2892.
- Lee, N. S., Dohjima, T., Bauer, G., Li, H., Li, M. J., Ehsani, A., Salvaterra, P., & Rossi, J. (2002). Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. *Nat. Biotechnol.* **20**(5): 500-505.

- Lee, S. B., & Kalluri, R. (2010). Mechanistic connection between inflammation and fibrosis. *Kidney Intl. Suppl.* **119**: S22-S26.
- Lee, S. K., & Kumar, P. (2009). Conditional RNAi: Towards a silent gene therapy. *Adv. Drug Deliv. Rev.* **61**(7-8): 650-664.
- Li, H., & Yang, B. B. (2013). Friend or foe: The role of microRNA in chemotherapy resistance. *Acta Pharmacol. Sin.* **34**(7): 870-879.
- Li, M. J., McMahon, R., Snyder, D. S., Yee, J. K., & Rossi, J. J. (2003). Specific killing of Ph⁺ chronic myeloid leukemia cells by a lentiviral vector delivered anti-bcr/abl small hairpin RNA. *Oligonucleotides* **13**(5): 401-409.
- Lim, G. C. C., Rampal, S., & Halimah, Y. (Eds.). (2008). *Cancer incidence in Peninsular Malaysia, 2003-2005*. Kuala Lumpur: National Cancer Registry.
- Liu, S., Ginestier, C., Ou, S. J., Clouthier, S. G., Patel, S. H., Monville, F., Korkaya, H., Heath, A., Dutcher, J., Kleer, C. G., Jung, Y., Dontu, G., Taichman, R., & Wicha, M. S. (2011). Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. *Cancer Res.* **71**(2): 614-624.
- Liu, Y. Y., Leboeuf, C., Shi, J. Y., Li, J. M., Wang, L., Shen, Y., Garcia, J. F., Shen, Z. X., Chen, Z., Janin, A., Chen, S. J., & Zhao, W. L. (2007). Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma. *Blood* **110**(1): 339-344.
- Livak, K. J., & Schmittgen, T. D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2^{(-Delta Delta C(T))} Method. *Methods* **25**(4): 402-408.
- Lokhorst, H. M., Lamme, T., de Smet, M., Klein, S., de Weger, R. A., van Oers, R., & Bloem, A. C. (1994). Primary tumour cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. *Blood* **84**(7): 2269-2277.
- Lonial, S., Vij, R., Harousseau, J. L., Facon, T., Moreau, P., Mazumder, A., Kaufman, J. L., Leleu, X., Tsao, L. C., Westland, C., Singhal, A. K., & Jagannath, S. (2012). Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. *J. Clin. Oncol.* **30**(16): 1953-1959.
- Lu, L. L., Liu, Y. J., Yang, S. G., Zhao, Q. J., Wang, X., Gong, W., Han, Z. B., Xu, Z. S., Lu, Y. X., Liu, D., Chen, Z. Z., & Han, Z. C. (2006). Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. *Haematologica* **91**(8): 1017-1026.
- Lu, Z. Y., Brailly, H., Wijdenes, J., Bataille, R., Rossi, J. F., & Klein, B. (1995). Measurement of whole body interleukin-6 (IL-6) production: Prediction of the efficacy of anti-IL-6 treatments. *Blood* **86**(8): 3123-3131.

- Luo, J., Ok Lee, S., Liang, L., Huang, C. K., Li, L., Wen, S., & Chang, C. (2014). Infiltrating bone marrow mesenchymal stem cells increase prostate cancer stem cell population and metastatic ability via secreting cytokines to suppress androgen receptor signaling. *Oncogene* **33**(21): 2768-2778.
- Machitani, M., Sakuraia, F., Katayamaa, K., Tachibanaa, M., Suzukib, T., Matsui, H., Yamaguchib, T., & Mizuguchia, H. (2014). Improving adenovirus vector-mediated RNAi efficiency by lacking the expression of virus-associated RNAs. *Virus Res.* **178**(2): 357-363.
- Maczuga, P., Verheij, J., van der Loos, C., van Logtenstein, R., Hooijer, G., Martier, R., Borel, F., Lubelski, J., Koornneef, A., Blits, B., van Deventer, S., Petry, H., & Konstantinova, P. (2014). Therapeutic expression of hairpins targeting apolipoprotein B100 induces phenotypic and transcriptome changes in murine liver. *Gene Ther.* **21**(1): 60-70.
- Magrangeas, F., Avet-Loiseau, H., Gouraud, W., Lode, L., Decaux, O., Godmer, P., Garderet, L., Voillat, L., Facon, T., Stoppa, A. M., Marit, G., Hulin, C., Casassus, P., Tiab, M., Voog, E., Randriamalala, E., Anderson, K. C., Moreau, P., Munshi, N. C., & Minvielle, S. (2013). Minor clone provides a reservoir for relapse in multiple myeloma. *Leukemia* **27**(2): 473-481.
- Mahindra, A., Hideshima, T., & Anderson, K. C. (2010). Multiple myeloma: Biology of the disease. *Blood Rev.* **24 Suppl 1**: S5-S11.
- Marrogi, A. J., Munshi, A., Merogi, A. J., Ohadike, Y., El-Habashi, A., Marrogi, O. L., & Freeman, S. M. (1997). Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma. *Int. J. Cancer* **74**(5): 492-501.
- Martin, F. T., Dwyer, R. M., Kelly, J., Khan, S., Murphy, J. M., Curran, C., Miller, N., Hennessy, E., Dockery, P., Barry, F. P., O'Brien, T., & Kerin, M. J. (2010). Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: Stimulation of epithelial to mesenchymal transition (EMT). *Breast Cancer Res. Treat.* **124**(2): 317-326.
- Martinez, M. A., Gutierrez, A., Armand-Ugon, M., Blanco, J., Parera, M., Gomez, J., Clotet, B., & Este, J. A. (2002). Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. *AIDS* **16**(18): 2385-2390.
- Masiero, M., Nardo, G., Indraccolo, S., & Favaro, E. (2007). RNA interference: Implications for cancer treatment. *Mol. Aspects Med.* **28**(1): 143-166.
- Matsukura, S., Jones, P. A., & Takai, D. (2003). Establishment of conditional vectors for hairpin siRNA knockdowns. *Nucleic Acids Res.* **31**(15): e77.
- McCaffrey, A. P., Nakai, H., Pandey, K., Huang, Z., Salazar, F. H., Xu, H., Wieland, S. F., Marion, P. L., & Kay, M. A. (2003). Inhibition of hepatitis B virus in mice by RNA interference. *Nat. Biotechnol.* **21**(6): 639-644.

- McEarchern, J. A., Oflazoglu, E., Francisco, L., McDonagh, C. F., Gordon, K. A., Stone, I., Klussman, K., Turcott, E., van Rooijen, N., Carter, P., Grewal, I. S., Wahl, A. F., & Law, C. L. (2007). Engineered anti-CD70 antibody with multiple effector functions exhibits *in vitro* and *in vivo* antitumor activities. *Blood* **109**(3): 1185-1192.
- McEarchern, J. A., Smith, L. M., McDonagh, C. F., Klussman, K., Gordon, K. A., Morris-Tilden, C. A., Duniho, S., Ryan, M., Boursalian, T. E., Carter, P. J., Grewal, I. S., & Law, C. L. (2008). Preclinical characterization of SGN-70, a humanized antibody directed against CD70. *Clin. Cancer Res.* **14**(23): 7763-7772.
- Menendez, P., Catalina, P., Rodriguez, R., Melen, G. J., Bueno, C., Arriero, M., Garcia-Sanchez, F., Lassaletta, A., Garcia-Sanz, R., & Garcia-Castro, J. (2009). Bone marrow mesenchymal stem cells from infants with MLL-AF4+ acute leukemia harbor and express the MLL-AF4 fusion gene. *J. Exp. Med.* **206**(13): 3131-3141.
- Michael-Robinson, J. M., Biemer-Huttmann, A., Purdie, D. M., Walsh, M. D., Simms, L. A., Biden, K. G., Young, J. P., Leggett, B. A., Jass, J. R., & Radford-Smith, G. L. (2001). Tumour infiltrating lymphocytes and apoptosis are independent features in colorectal cancer stratified according to microsatellite instability status. *Gut* **48**(3): 360-366.
- Miller, V. M., Gouvion, C. M., Davidson, B. L., & Paulson, H. L. (2004). Targeting Alzheimer's disease genes with RNA interference: An efficient strategy for silencing mutant alleles. *Nucleic Acids Res.* **32**(2): 661-668.
- Miller, V. M., Xia, H., Marrs, G. L., Gouvion, C. M., Lee, G., Davidson, B. L., & Paulson, H. L. (2003). Allele-specific silencing of dominant disease genes. *Proc. Natl. Acad. Sci. USA* **100**(12): 7195-7200.
- Mitsiades, C. S., & Chen-Kiang, S. (2013). Immunomodulation as a therapeutic strategy in the treatment of multiple myeloma. *Crit Rev Oncol Hematol* **88 Suppl 1**: S5-13.
- Mitsiades, C. S., Mitsiades, N. S., Munshi, N. C., Richardson, P. G., & Anderson, K. C. (2006). The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: Interplay of growth factors, their receptors and stromal interactions. *Eur. J. Cancer* **42**(11): 1564-1573.
- Moreau, P., Housseau, J. L., Wijdenes, J., Morineau, N., Milpied, N., & Bataille, R. (2000). A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. *Br. J. Haematol.* **109**(3): 661-664.
- Moreaux, J., Legouffe, E., Jourdan, E., Quittet, P., Reme, T., Lugagne, C., Moine, P., Rossi, J. F., Klein, B., & Tarte, K. (2004). BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. *Blood* **103**(8): 3148-3157.

- Mukherjee, S., Raje, N., Schoonmaker, J. A., Liu, J. C., Hideshima, T., Wein, M. N., Jones, D. C., Vallet, S., Boussein, M. L., Pozzi, S., Chhetri, S., Seo, Y. D., Aronson, J. P., Patel, C., Fulciniti, M., Purton, L. E., Glimcher, L. H., Lian, J. B., Stein, G., Anderson, K. C., & Scadden, D. T. (2008). Pharmacologic targeting of a stem/progenitor population *in vivo* is associated with enhanced bone regeneration in mice. *J. Clin. Invest.* **118**(2): 491-504.
- Musto, P., Falcone, A., Sanpaolo, G., Bodenizza, C., Cascavilla, N., Melillo, L., Scalzulli, P. R., Dell'Olio, M., La Sala, A., Mantuano, S., Nobile, M., & Carella, A. M. (2003). Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: Results of a randomized trial. *Leuk. Lymphoma* **44**(9): 1545-1548.
- Nakai, N., Kishida, T., Shin-Ya, M., Imanishi, J., Ueda, Y., Kishimoto, S., & Mazda, O. (2007). Therapeutic RNA interference of malignant melanoma by electrotransfer of small interfering RNA targeting Mitf. *Gene Ther.* **14**(4): 357-365.
- Nakamizo, A., Marini, F., Amano, T., Khan, A., Studeny, M., Gumin, J., Chen, J., Hentschel, S., Vecil, G., Dembinski, J., Andreeff, M., & Lang, F. F. (2005). Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. *Cancer Res.* **65**(8): 3307-3318.
- Neri, P., Kumar, S., Fulciniti, M. T., Vallet, S., Chhetri, S., Mukherjee, S., Tai, Y., Chauhan, D., Tassone, P., Venuta, S., Munshi, N. C., Hideshima, T., Anderson, K. C., & Raje, N. (2007). Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. *Clin. Cancer Res.* **13**(19): 5903-5909.
- Nieth, C., Priebisch, A., Stege, A., & Lage, H. (2003). Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). *FEBS Lett.* **545**(2-3): 144-150.
- Nilsson, K., Bennich, H., Johansson, S. G., & Ponten, J. (1970). Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient. *Clin Exp Immunol* **7**(4): 477-489.
- Noonan, K., Marchionni, L., Anderson, J., Pardoll, D., Roodman, G. D., & Borrello, I. (2010). A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. *Blood* **116**(18): 3554-3563.
- Novina, C. D., Murray, M. F., Dykxhoorn, D. M., Beresford, P. J., Riess, J., Lee, S. K., Collman, R. G., Lieberman, J., Shankar, P., & Sharp, P. A. (2002). siRNA-directed inhibition of HIV-1 infection. *Nat. Med.* **8**(7): 681-686.
- Ogata, A., Chauhan, D., Teoh, G., Treon, S. P., Urashima, M., Schlossman, R. L., & Anderson, K. C. (1997). IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. *J. Immunol.* **159**(5): 2212-2221.
- Olson, S. D., Kambal, A., Pollock, K., Mitchell, G. M., Stewart, H., Kalomoiris, S., Cary, W., Nacey, C., Pepper, K., & Nolta, J. A. (2012a). Examination of

mesenchymal stem cell-mediated RNAi transfer to Huntington's disease affected neuronal cells for reduction of huntingtin. *Mol. Cell Neurosci.* **49**(3): 271-281.

- Olson, S. D., Pollock, K., Kambal, A., Cary, W., Mitchell, G. M., Tempkin, J., Stewart, H., McGee, J., Bauer, G., Kim, H. S., Tempkin, T., Wheelock, V., Annett, G., Dunbar, G., & Nolte, J. A. (2012b). Genetically engineered mesenchymal stem cells as a proposed therapeutic for Huntington's disease. *Mol. Neurobiol.* **45**(1): 87-98.
- Orlowski, R. Z., Gercheva, L., Williams, C., Sutherland, H., Robak, T., Masszi, T., Goranova-Marinova, V., Dimopoulos, M. A., Cavenagh, J. D., Spicka, I., Maiolino, A., Suvorov, A., Blade, J., Samoylova, O., Puchalski, T. A., Reddy, M., Bandekar, R., van de Velde, H., Xie, H., & Rossi, J. F. (2015). A phase II, randomized, double-blind, placebo-controlled study of Siltuximab (anti-IL-6 mAb) and Bortezomib versus Bortezomib alone in patients with relapsed or refractory multiple myeloma. *Am. J. Hematol.* **90**(1): 42-49.
- Otsuki, T., Yata, K., Sakaguchi, H., Uno, M., Fujii, T., Wada, H., Sugihara, T., & Ueki, A. (2002). IL-10 in myeloma cells. *Leuk. Lymphoma* **43**(5): 969-974.
- Overman, M. J., Feng, L., Pro, B., McLaughlin, P., Hess, M., Samaniego, F., Younes, A., Romaguera, J. E., Hagemester, F. B., Kwak, L., Cabanillas, F., Rodriguez, M. A., & Fayad, L. E. (2008). The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma. *Ann. Oncol.* **19**(3): 553-559.
- Ozawa, K., Sato, K., Oh, I., Ozaki, K., Uchibori, R., Obara, Y., Kikuchi, Y., Ito, T., Okada, T., Urabe, M., Mizukami, H., & Kume, A. (2008). Cell and gene therapy using mesenchymal stem cells (MSCs). *J. Autoimmun.* **30**(3): 121-127.
- Paddison, P. J., Caudy, A. A., Bernstein, E., Hannon, G. J., & Conklin, D. S. (2002). Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. *Genes Dev.* **16**(8): 948-958.
- Park, W. S., Miyano-Kurosaki, N., Hayafune, M., Nakajima, E., Matsuzaki, T., Shimada, F., & Takaku, H. (2002). Prevention of HIV-1 infection in human peripheral blood mononuclear cells by specific RNA interference. *Nucleic Acids Res.* **30**(22): 4830-4835.
- Partida-Sanchez, S., Cockayne, D. A., Monard, S., Jacobson, E. L., Oppenheimer, N., Garvy, B., Kusser, K., Goodrich, S., Howard, M., Harmsen, A., Randall, T. D., & Lund, F. E. (2001). Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance *in vivo*. *Nat. Med.* **7**(11): 1209-1216.
- Paul, C. P., Good, P. D., Winer, I., & Engelke, D. R. (2002). Effective expression of small interfering RNA in human cells. *Nat. Biotechnol.* **20**(5): 505-508.

- Pene, F., Claessens, Y. E., Muller, O., Viguie, F., Mayeux, P., Dreyfus, F., Lacombe, C., & Bouscary, D. (2002). Role of phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis of multiple myeloma cells. *Oncogene* **21**(43): 6587-6597.
- Pereboeva, L., Komarova, S., Mikheeva, G., Krasnykh, V., & Curiel, D. T. (2003). Approaches to utilize mesenchymal progenitor cells as cellular vehicles. *Stem Cells* **21**(4): 389-404.
- Perez-Martinez, F. C., Carrion, B., Lucio, M. I., Rubio, N., Herrero, M. A., Vazquez, E., & Cena, V. (2012). Enhanced docetaxel-mediated cytotoxicity in human prostate cancer cells through knockdown of cofilin-1 by carbon nanohorn delivered siRNA. *Biomaterials* **33**(32): 8152-8159.
- Picker, L. J., & Siegelman, M. H. (1999). *Lymphoid tissues and organs* (4 ed.). Philadelphia, PA.: Lippincott-Raven.
- Pinkenburg, O., Platz, J., Beisswenger, C., Vogelmeier, C., & Bals, R. (2004). Inhibition of NF-kappaB mediated inflammation by siRNA expressed by recombinant adeno-associated virus. *J. Virol. Methods* **120**(1): 119-122.
- Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., Moorman, M. A., Simonetti, D. W., Craig, S., & Marshak, D. R. (1999). Multilineage potential of adult human mesenchymal stem cells. *Science* **284**(5411): 143-147.
- Plowman, J., Dykes, D. J., Hollingshead, M., Simpson-Herren, L., & Alley, M. C. (2002). Human tumour xenograft models in NCI drug development. In B. Teicher (Ed.), *Anticancer drug development guide: Preclinical screening, clinical trials and approval* (pp. 101-125). Totowa NJ: Humana Press Inc.
- Podar, K., & Anderson, K. C. (2005). The pathophysiologic role of VEGF in hematologic malignancies: Therapeutic implications. *Blood* **105**(4): 1383-1395.
- Podar, K., & Anderson, K. C. (2010). *The pathophysiologic role of the bone marrow environment and its niches in multiple myeloma*. (2 ed. Vol. 3): Academic Press.
- Podar, K., Chauhan, D., & Anderson, K. C. (2009). Bone marrow microenvironment and the identification of new targets for myeloma therapy. *Leukemia* **23**(1): 10-24.
- Podar, K., Mostoslavsky, G., Sattler, M., Tai, Y. T., Hayashi, T., Catley, L. P., Hideshima, T., Mulligan, R. C., Chauhan, D., & Anderson, K. C. (2004). Critical role for hematopoietic cell kinase (Hck)-mediated phosphorylation of Gab1 and Gab2 docking proteins in interleukin 6-induced proliferation and survival of multiple myeloma cells. *J. Biol. Chem.* **279**(20): 21658-21665.
- Podar, K., Richardson, P. G., Hideshima, T., Chauhan, D., & Anderson, K. C. (2007). The malignant clone and the bone-marrow environment. *Best Pract. Res. Clin. Haematol.* **20**(4): 597-612.

- Prabhala, R. H., Pelluru, D., Fulciniti, M., Prabhala, H. K., Nanjappa, P., Song, W., Pai, C., Amin, S., Tai, Y. T., Richardson, P. G., Ghobrial, I. M., Treon, S. P., Daley, J. F., Anderson, K. C., Kutok, J. L., & Munshi, N. C. (2010). Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. *Blood* **115**(26): 5385-5392.
- Raaijmakers, M. H., Mukherjee, S., Guo, S., Zhang, S., Kobayashi, T., Schoonmaker, J. A., Ebert, B. L., Al-Shahrour, F., Hasserjian, R. P., Scadden, E. O., Aung, Z., Matza, M., Merckenschlager, M., Lin, C., Rommens, J. M., & Scadden, D. T. (2010). Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. *Nature* **464**(7290): 852-857.
- Rao, D. D., Vorhies, J. S., Senzer, N., & Nemunaitis, J. (2009). siRNA vs. shRNA: Similarities and differences. *Adv. Drug Deliv. Rev.* **61**(9): 746-759.
- Reagan, M. R., & Ghobrial, I. M. (2012). Multiple myeloma mesenchymal stem cells: Characterization, origin, and tumor-promoting effects. *Clin. Cancer Res.* **18**(2): 342-349.
- Reiser, J., Zhang, X. Y., Hemenway, C. S., Mondal, D., Pradhan, L., & La Russa, V. F. (2005). Potential of mesenchymal stem cells in gene therapy approaches for inherited and acquired diseases. *Expert Opin. Biol. Ther.* **5**(12): 1571-1584.
- Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J. L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San-Miguel, J. F., Blade, J., Boccadoro, M., Cavenagh, J., Dalton, W. S., Boral, A. L., Esseltine, D. L., Porter, J. B., Schenkein, D., & Anderson, K. C. (2005). Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. *N. Engl. J. Med.* **352**(24): 2487-2498.
- Ries, L. A. G., Harkins, D., Krapcho, M., Mariotto, A., Miller, B. A., Feuer, E. J., Clegg, L., Eisner, M. P., Horner, M. J., Howlader, N., M., H., Hankey, B. F., & Edwards, B. K. (2006). SEER cancer statistics review, 1975-2003, National Cancer Institute. Bethesda, MD Retrieved 16/11/2014, 2014 from http://seer.cancer.gov/csr/1975_2003/
- Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Jr., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., Swain, S. M., Pisansky, T. M., Fehrenbacher, L., Kutteh, L. A., Vogel, V. G., Visscher, D. W., Yothers, G., Jenkins, R. B., Brown, A. M., Dakhil, S. R., Mamounas, E. P., Lingle, W. L., Klein, P. M., Ingle, J. N., & Wolmark, N. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. *N. Engl. J. Med.* **353**(16): 1673-1684.
- Roodman, G. D. (2004). Pathogenesis of myeloma bone disease. *Blood Cells Mol. Dis.* **32**(2): 290-292.
- Ropponen, K. M., Eskelinen, M. J., Lipponen, P. K., Alhava, E., & Kosma, V. M. (1997). Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. *J. Pathol.* **182**(3): 318-324.

- Sahara, N., Takeshita, A., Ono, T., Sugimoto, Y., Kobayashi, M., Shigeno, K., Nakamura, S., Shinjo, K., Naito, K., Shibata, K., Otsuki, T., Hayashi, H., & Ohnishi, K. (2006). Role for interleukin-6 and insulin-like growth factor-I via PI3-K/Akt pathway in the proliferation of CD56- and CD56+ multiple myeloma cells. *Exp. Hematol.* **34**(6): 736-744.
- Sanceau, J., Poupon, M. F., Delattre, O., Sastre-Garau, X., & Wietzerbin, J. (2002). Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide. *Oncogene* **21**(50): 7700-7709.
- Sansone, P., & Bromberg, J. (2012). Targeting the interleukin-6/Jak/Stat pathway in human malignancies. *J. Clin. Oncol.* **30**(9): 1005-1014.
- Santonocito, A. M., Consoli, U., Bagnato, S., Milone, G., Palumbo, G. A., Di Raimondo, F., Stagno, F., Guglielmo, P., & Giustolisi, R. (2004). Flow cytometric detection of aneuploid CD38(++) plasma cells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients. *Leuk. Res.* **28**(5): 469-477.
- Sato, Y., Araki, H., Kato, J., Nakamura, K., Kawano, Y., Kobune, M., Sato, T., Miyanishi, K., Takayama, T., Takahashi, M., Takimoto, R., Iyama, S., Matsunaga, T., Ohtani, S., Matsuura, A., Hamada, H., & Niitsu, Y. (2005). Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion. *Blood* **106**(2): 756-763.
- Schwarz, D. S., Ding, H., Kennington, L., Moore, J. T., Schelter, J., Burchard, J., Linsley, P. S., Aronin, N., Xu, Z., & Zamore, P. D. (2006). Designing siRNA that distinguish between genes that differ by a single nucleotide. *PLoS Genet.* **2**(9): e140.
- Sehgal, P. B., Zilberstein, A., Ruggieri, R. M., May, L. T., Ferguson-Smith, A., Slate, D. L., Revel, M., & Ruddle, F. H. (1986). Human chromosome 7 carries the beta 2 interferon gene. *Proc. Natl. Acad. Sci. USA* **83**(14): 5219-5222.
- Semenza, G. L. (2003). Targeting HIF-1 for cancer therapy. *Nat. Rev. Cancer* **3**(10): 721-732.
- Shanafelt, T. D., Gunderson, H., & Call, T. G. (2010). Commentary: Chronic lymphocytic leukemia - The price of progress. *The oncologist* **15**(6): 601-602.
- Shaughnessy, A. F. (2012). Monoclonal antibodies: Magic bullets with a hefty price tag. *BMJ* **345**: e8346.
- Shen, H. L., Xu, W., Wu, Z. Y., Zhou, L. L., Qin, R. J., & Tang, H. R. (2007). Vector-based RNAi approach to isoform-specific downregulation of vascular endothelial growth factor (VEGF)165 expression in human leukemia cells. *Leuk. Res.* **31**(4): 515-521.

- Shi, Y., Tong, M., Wu, Y., Yang, Z., Hoffman, R. M., Zhang, Y., Tian, Y., Qi, M., Lin, Y., Liu, Y., Dai, L., Sun, Y., & Wang, Z. (2013). VEGF-C shRNA inhibits pancreatic cancer growth and lymphangiogenesis in an orthotopic fluorescent nude mouse model. *Anticancer Res.* **33**(2): 409-417.
- Shipman, C. M., & Croucher, P. I. (2003). Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. *Cancer Res.* **63**(5): 912-916.
- Siegel, R., Naishadham, D., & Jemal, A. (2012). Cancer statistics, 2012. *CA Cancer J. Clin.* **62**(1): 10-29.
- Simonson, W. T. N., & Allison, K. H. (2010). Tumour-infiltrating lymphocytes in cancer: Implications for the diagnostic pathologist. *Diagn. Histopathol.* **17**(2): 80-90.
- Simpson, R. J., Hammacher, A., Smith, D. K., Matthews, J. M., & Ward, L. D. (1997). Interleukin-6: Structure-function relationships. *Protein Sci.* **6**(5): 929-955.
- Siolas, D., Lerner, C., Burchard, J., Ge, W., Linsley, P. S., Paddison, P. J., Hannon, G. J., & Cleary, M. A. (2005). Synthetic shRNAs as potent RNAi triggers. *Nat. Biotechnol.* **23**(2): 227-231.
- Sioud, M. (2004). Therapeutics siRNAs. *Trends Pharmacol. Sci.* **25**(1): 22-28.
- Sirohi, B., & Powles, R. (2004). Multiple myeloma. *Lancet* **363**(9412): 875-887.
- Sledz, C. A., Holko, M., de Veer, M. J., Silverman, R. H., & Williams, B. R. (2003). Activation of the interferon system by short-interfering RNAs. *Nat. Cell Biol.* **34**(9): 263-264.
- Song, E., Lee, S. K., Wang, J., Ince, N., Ouyang, N., Min, J., Chen, J., Shankar, P., & Lieberman, J. (2003). RNA interference targeting Fas protects mice from fulminant hepatitis. *Nat. Med.* **9**(3): 347-351.
- Sonpavde, G. (2003). Bevacizumab in renal-cell cancer. *N. Engl. J. Med.* **349**(17): 1674.
- Spina, M., Simonelli, C., & Tirelli, U. (2007). Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. *J. Clin. Oncol.* **25**(6): e7.
- Sprynski, A. C., Hose, D., Caillot, L., Reme, T., Shaughnessy, J. D., Jr., Barlogie, B., Seckinger, A., Moreaux, J., Hundemer, M., Jourdan, M., Meissner, T., Jauch, A., Mahtouk, K., Kassambara, A., Bertsch, U., Rossi, J. F., Goldschmidt, H., & Klein, B. (2009). The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. *Blood* **113**(19): 4614-4626.

- Stevenson, J. D., Wall, C., Patel, A., & Lim, J. (2014). Multiple myeloma: A review. *Orthop. Trauma* **28**(3): 187-193.
- Stoopler, E. T., Vogl, D. T., & Stadtmauer, E. A. (2007). Medical management update: Multiple myeloma. *Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.* **103**(5): 599-609.
- Studený, M., Marini, F. C., Champlin, R. E., Zompetta, C., Fidler, I. J., & Andreeff, M. (2002). Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. *Cancer Res.* **62**(13): 3603-3608.
- Studený, M., Marini, F. C., Dembinski, J. L., Zompetta, C., Cabreira-Hansen, M., Bekele, B. N., Champlin, R. E., & Andreeff, M. (2004). Mesenchymal stem cells: Potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. *J. Natl. Cancer Inst.* **96**(21): 1593-1603.
- Sui, G., Soohoo, C., Affar el, B., Gay, F., Shi, Y., & Forrester, W. C. (2002). A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. *Proc. Natl. Acad. Sci. USA* **99**(8): 5515-5520.
- Sumimoto, H., Miyagishi, M., Miyoshi, H., Yamagata, S., Shimizu, A., Taira, K., & Kawakami, Y. (2004). Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. *Oncogene* **23**(36): 6031-6039.
- Sun, S., Guo, Z., Xiao, X., Liu, B., Liu, X., Tang, P. H., & Mao, N. (2003). Isolation of mouse marrow mesenchymal progenitors by a novel and reliable method. *Stem Cells* **21**(5): 527-535.
- Tai, Y. T., Li, X. F., Breitkreutz, I., Song, W., Neri, P., Catley, L., Podar, K., Hideshima, T., Chauhan, D., Raje, N., Schlossman, R., Richardson, P., Munshi, N. C., & Anderson, K. C. (2006). Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. *Cancer Res.* **66**(13): 6675-6682.
- Takei, Y., Kadomatsu, K., Yuzawa, Y., Matsuo, S., & Muramatsu, T. (2004). A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. *Cancer Res.* **64**(10): 3365-3370.
- Tamura, H., Ishibashi, M., Yamashita, T., Tanosaki, S., Okuyama, N., Kondo, A., Hyodo, H., Shinya, E., Takahashi, H., Dong, H., Tamada, K., Chen, L., Dan, K., & Ogata, K. (2013). Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. *Leukemia* **27**(2): 464-472.
- Tassone, P., Forciniti, S., Galea, E., Savino, R., Turco, M. C., Iacopino, P., Tagliaferri, P., Morrone, G., Ciliberto, G., & Venuta, S. (2000). Synergistic induction of growth arrest and apoptosis of human myeloma cells by the IL-6 super-antagonist Sant7 and Dexamethasone. *Cell Death Differ.* **7**(3): 327-328.

- Tassone, P., Galea, E., Forciniti, S., Tagliaferri, P., & Venuta, S. (2002). The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells. *Int. J. Oncol.* **21**(4): 867-873.
- Tassone, P., Neri, P., Carrasco, D. R., Burger, R., Goldmacher, V. S., Fram, R., Munshi, V., Shamma, M. A., Catley, L., Jacob, G. S., Venuta, S., Anderson, K. C., & Munshi, N. C. (2005). A clinically relevant SCID-hu *in vivo* model of human multiple myeloma. *Blood* **106**(2): 713-716.
- Teoh, G., & Anderson, K. C. (1997). Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. *Hematol. Oncol. Clin. N.* **11**(1): 27-42.
- Terpos, E., Sezer, O., Croucher, P., & Dimopoulos, M. A. (2007). Myeloma bone disease and proteasome inhibition therapies. *Blood* **110**(4): 1098-1104.
- Tinhofer, I., Marschitz, I., Henn, T., Egle, A., & Greil, R. (2000). Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. *Blood* **95**(2): 610-618.
- Tosi, P., Gamberi, B., & Giuliani, N. (2006). Biology and treatment of multiple myeloma. *Biol. Blood Marrow Transplant.* **12**(1 Suppl 1): 81-86.
- Travlos, G. S. (2006). Normal structure, function, and histology of the bone marrow. *Toxicol. Pathol.* **34**(5): 548-565.
- Trikha, M., Corringham, R., Klein, B., & Rossi, J. F. (2003). Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: A review of the rationale and clinical evidence. *Clin. Cancer Res.* **9**(13): 4653-4665.
- Trimboli, A. J., Cantemir-Stone, C. Z., Li, F., Wallace, J. A., Merchant, A., Creasap, N., Thompson, J. C., Caserta, E., Wang, H., Chong, J. L., Naidu, S., Wei, G., Sharma, S. M., Stephens, J. A., Fernandez, S. A., Gurcan, M. N., Weinstein, M. B., Barsky, S. H., Yee, L., Rosol, T. J., Stromberg, P. C., Robinson, M. L., Pepin, F., Hallett, M., Park, M., Ostrowski, M. C., & Leone, G. (2009). Pten in stromal fibroblasts suppresses mammary epithelial tumours. *Nature* **461**(7267): 1084-1091.
- Uchiyama, H., Barut, B. A., Chauhan, D., Cannistra, S. A., & Anderson, K. C. (1992). Characterization of adhesion molecules on human myeloma cell lines. *Blood* **80**(9): 2306-2314.
- Uchiyama, H., Barut, B. A., Mohrbacher, A. F., Chauhan, D., & Anderson, K. C. (1993). Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. *Blood* **82**(12): 3712-3720.
- van der Veer, M. S., de Weers, M., van Kessel, B., Bakker, J. M., Wittebol, S., Parren, P. W., Lokhorst, H. M., & Mutis, T. (2011). Towards effective immunotherapy of myeloma: Enhanced elimination of myeloma cells by

combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. *Haematologica* **96**(2): 284-290.

- Van Etten, R. A., & Shannon, K. M. (2004). Focus on myeloproliferative diseases and myelodysplastic syndromes. *Cancer Cell*. **6**(6): 547-552.
- van Marion, A. M. W., Lokhorst, H. M., & van den Tweel, J. G. (2003). Pathology of multiple myeloma. *Curr. Diagn. Pathol.* **9**(5): 322-327.
- van Rhee, F., Szmania, S. M., Dillon, M., van Abbema, A. M., Li, X., Stone, M. K., Garg, T. K., Shi, J., Moreno-Bost, A. M., Yun, R., Balasa, B., Ganguly, B., Chao, D., Rice, A. G., Zhan, F., Shaughnessy, J. D., Jr., Barlogie, B., Yaccoby, S., & Afar, D. E. (2009). Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. *Mol. Cancer Ther.* **8**(9): 2616-2624.
- Van Riet, I., De Greef, C., Aharchi, F., Woischwill, C., De Waele, M., Bakkus, M., Lacor, P., Schots, R., & Van Camp, B. (1997). Establishment and characterization of a human stroma-dependent myeloma cell line (MM5.1) and its stroma-independent variant (MM5.2). *Leukemia* **11**(2): 284-293.
- van Zaanen, H. C. T., Koopmans, R. P., Aarden, L. A., Rensink, H. J., Stouthard, J. M., Warnaar, S. O., Lokhorst, H. M., & van Oers, M. H. (1996). Endogenous interleukin-6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. *J. Clin. Invest.* **98**(6): 1441-1448.
- van Zaanen, H. C. T., Lokhorst, H. M., Aarden, L. A., Rensink, H. J., Warnaar, S. O., van der Lelie, J., & van Oers, M. H. (1998). Chimeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: A phase I dose-escalating study. *Br. J. Haematol.* **102**(3): 783-790.
- Vlassov, A. V., Korba, B., Farrar, K., Mukerjee, S., Seyhan, A. A., Ilves, H., Kaspar, R. L., Leake, D., Kazakov, S. A., & Johnston, B. H. (2007). shRNAs targeting hepatitis C: Effects of sequence and structural features, and comparison with siRNA. *Oligonucleotides* **17**(2): 223-236.
- Voorhees, P. M., Chen, Q., Kuhn, D. J., Small, G. W., Hunsucker, S. A., Strader, J. S., Corringham, R. E., Zaki, M. H., Nemeth, J. A., & Orlowski, R. Z. (2007). Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. *Clin. Cancer Res.* **13**(21): 6469-6478.
- Voorhees, P. M., Chen, Q., Small, G. W., Kuhn, D. J., Hunsucker, S. A., Nemeth, J. A., & Orlowski, R. Z. (2009). Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. *Br. J. Haematol.* **145**(4): 481-490.
- Voorhees, P. M., Manges, R. F., Sonneveld, P., Jagannath, S., Somlo, G., Krishnan, A., Lentzsch, S., Frank, R. C., Zweegman, S., Wijermans, P. W., Orlowski, R. Z., Kranenburg, B., Hall, B., Casneuf, T., Qin, X., van de Velde, H., Xie, H., & Thomas, S. K. (2013). A phase 2 multicentre study of siltuximab, an

anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. *Br J Haematol* **161**(3): 357-366.

- Wagner, W., Horn, P., Castoldi, M., Diehlmann, A., Bork, S., Saffrich, R., Benes, V., Blake, J., Pfister, S., Eckstein, V., & Ho, A. D. (2008). Replicative senescence of mesenchymal stem cells: a continuous and organized process. *PLoS One* **3**(5): e2213.
- Walker, B. A., Wardell, C. P., Melchor, L., Brioli, A., Johnson, D. C., Kaiser, M. F., Mirabella, F., Lopez-Corral, L., Humphray, S., Murray, L., Ross, M., Bentley, D., Gutierrez, N. C., Garcia-Sanz, R., San Miguel, J., Davies, F. E., Gonzalez, D., & Morgan, G. J. (2014). Intracлонаl heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. *Leukemia* **28**(2): 384-390.
- Walker, B. A., Wardell, C. P., Melchor, L., Hulkki, S., Potter, N. E., Johnson, D. C., Fenwick, K., Kozarewa, I., Gonzalez, D., Lord, C. J., Ashworth, A., Davies, F. E., & Morgan, G. J. (2012). Intracлонаl heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. *Blood* **120**(5): 1077-1086.
- Walkley, C. R., Olsen, G. H., Dworkin, S., Fabb, S. A., Swann, J., McArthur, G. A., Westmoreland, S. V., Chambon, P., Scadden, D. T., & Purton, L. E. (2007a). A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. *Cell* **129**(6): 1097-1110.
- Walkley, C. R., Shea, J. M., Sims, N. A., Purton, L. E., & Orkin, S. H. (2007b). Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. *Cell* **129**(6): 1081-1095.
- Wall, N. R., & Shi, Y. (2003). Small RNA: Can RNA interference be exploited for therapy? *Lancet* **362**(9393): 1401-1403.
- Wallner, L., Dai, J., Escara-Wilke, J., Zhang, J., Yao, Z., Lu, Y., Trikha, M., Nemeth, J. A., Zaki, M. H., & Keller, E. T. (2006). Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. *Cancer Res.* **66**(6): 3087-3095.
- Wang, H., Lathia, J. D., Wu, Q. L., Wang, J. L., Li, Z. Z., Heddleston, J. M., Eyler, C. E., Elderbroom, J., Gallagher, J., Schuschu, J., Macswords, J., Cao, Y. T., McLendon, R. E., Wang, X. F., Hjelmeland, A. B., & Rich, J. N. (2009). Targeting interleukin-6 signalling suppresses glioma stem cell survival and tumor growth. *Stem Cells* **27**(10): 2393-2404.
- Wang, Y., Zhu, H., Quan, L., Zhou, C., Bai, J., Zhang, G., Zhan, Q., & Xu, N. (2005a). Downregulation of survivin by RNAi inhibits the growth of esophageal carcinoma cells. *Cancer Biol. Ther.* **4**(9): 974-978.

- Wang, Y. L., Liu, W., Wada, E., Murata, M., Wada, K., & Kanazawa, I. (2005b). Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA. *Neurosci. Res.* **53**(3): 241-249.
- Wang, Z., Rao, D. D., Senzer, N., & Nemunaitis, J. (2011). RNA interference and cancer therapy. *Pharm. Res.* **28**(12): 2983-2995.
- Wannenes, F., Ciafre, S. A., Niola, F., Frajese, G., & Farace, M. G. (2005). Vector-based RNA interference against vascular endothelial growth factor-A significantly limits vascularization and growth of prostate cancer *in vivo*. *Cancer Gene Ther.* **12**(12): 926-934.
- Whitey, J. M. E., & Crompton, M. R. (2005). RNA Interference: A New Targeted Tumour Therapy? *Curr. Cancer Ther. Rev.* **1**(1): 11-17.
- Wingo, P. A., Ries, L. A., Rosenberg, H. M., Miller, D. S., & Edwards, B. K. (1998). Cancer incidence and mortality, 1973-1995: A report card for the U.S. *Cancer* **82**(6): 1197-1207.
- Witting, S. R., Brown, M., Saxena, R., Nabinger, S., & Morral, N. (2008). Helper-dependent adenovirus-mediated short hairpin RNA expression in the liver activates the interferon response. *J. Biol. Chem.* **283**(4): 2120-2128.
- Wu, Z., Li, X., Zeng, Y., Zhuang, X., Shen, H., Zhu, H., Liu, H., & Xiao, H. (2011). *In vitro* and *in vivo* inhibition of MRP gene expression and reversal of multidrug resistance by siRNA. *Basic Clin. Pharmacol. Toxicol.* **108**(3): 177-184.
- Xie, J. Y., Li, M. X., Xiang, D. B., Mou, J. H., Qing, Y., Zeng, L. L., Yang, Z. Z., Guan, W., & Wang, D. (2010). Elevated expression of APE1/Ref-1 and its regulation on IL-6 and IL-8 in bone marrow stromal cells of multiple myeloma. *Clin. Lymphoma Myeloma Leuk.* **10**(5): 385-393.
- Xin, H., Kanehira, M., Mizuguchi, H., Hayakawa, T., Kikuchi, T., Nukiwa, T., & Saijo, Y. (2007). Targeted delivery of CX3CL1 to multiple lung tumors by mesenchymal stem cells. *Stem Cells* **25**(7): 1618-1626.
- Xu, M. H., Gao, X., Luo, D., Zhou, X. D., Xiong, W., & Liu, G. X. (2014). EMT and acquisition of stem cell-like properties are involved in spontaneous formation of tumorigenic hybrids between lung cancer and bone marrow-derived mesenchymal stem cells. *PLoS One* **9**(2): e87893.
- Xu, S., Menu, E., De Becker, A., Van Camp, B., Vanderkerken, K., & Van Riet, I. (2012). Bone marrow-derived mesenchymal stromal cells are attracted by multiple myeloma cell-produced chemokine CCL25 and favor myeloma cell growth *in vitro* and *in vivo*. *Stem Cells* **30**(2): 266-279.
- Yam, P. Y., Li, S., Wu, J., Hu, J., Zaia, J. A., & Yee, J. K. (2002). Design of HIV vectors for efficient gene delivery into human hematopoietic cells. *Mol Ther* **5**(4): 479-484.

- Yamato, K., Fen, J., Kobuchi, H., Nasu, Y., Yamada, T., Nishihara, T., Ikeda, Y., Kizaki, M., & Yoshinouchi, M. (2006). Induction of cell death in human papillomavirus 18-positive cervical cancer cells by E6 siRNA. *Cancer Gene Ther.* **13**(3): 234-241.
- Yang, F. C., Ingram, D. A., Chen, S., Zhu, Y., Yuan, J., Li, X., Yang, X., Knowles, S., Horn, W., Li, Y., Zhang, S., Yang, Y., Vakili, S. T., Yu, M., Burns, D., Robertson, K., Hutchins, G., Parada, L. F., & Clapp, D. W. (2008). Nf1-dependent tumors require a microenvironment containing Nf1^{+/-} and c-kit-dependent bone marrow. *Cell* **135**(3): 437-448.
- Yang, G., Cai, K. Q., Thompson-Lanza, J. A., Bast, R. C. J., & Liu, J. (2004). Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. *J. Biol. Chem.* **279**(6): 4339-4345.
- Yang, G., Thompson, J. A., Fang, B., & Liu, J. (2003). Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumor growth in a model of human ovarian cancer. *Oncogene* **22**(36): 5694-5701.
- Yang, H. Y., Vonk, L. A., Licht, R., van Boxtel, A. M., Bekkers, J. E., Kragten, A. H., Hein, S., Varghese, O. P., Howard, K. A., Oner, F. C., Dhert, W. J., & Creemers, L. B. (2014). Cell type and transfection reagent-dependent effects on viability, cell content, cell cycle and inflammation of RNAi in human primary mesenchymal cells. *Eur. J. Pharm. Sci.* **53**: 35-44.
- Yang, J., & Yi, Q. (2011). Therapeutic monoclonal antibodies for multiple myeloma: An update and future perspectives. *Am. J. Blood Res.* **1**(1): 22-33.
- Yano, J., Hirabayashi, K., Nakagawa, S., Yamaguchi, T., Nogawa, M., Kashimori, I., Naito, H., Kitagawa, H., Ishiyama, K., Ohgi, T., & Irimura, T. (2004). Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. *Clin. Cancer Res.* **10**(22): 7721-7726.
- Yao, X., Huang, J., Zhong, H., Shen, N., Faggioni, R., Fung, M., & Yao, Y. (2014). Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. *Pharmacol Ther* **141**(2): 125-139.
- Yu, J. Y., DeRuiter, S. L., & Turner, D. L. (2002). RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. *Proc. Natl. Acad. Sci. USA* **99**(9): 6047-6052.
- Yuan, J., Kramer, A., Matthes, Y., Yan, R., Spankuch, B., Gatje, R., Knecht, R., Kaufmann, M., & Strebhardt, K. (2006). Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest *in vivo*. *Oncogene* **25**(12): 1753-1762.
- Zamore, P. D., Tuschl, T., Sharp, P. A., & Bartel, D. P. (2000). RNAi: Double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. *Cell* **101**(1): 25-33.

- Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., Rubin, S. C., & Coukos, G. (2003). Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. *N. Engl. J. Med.* **348**(3): 203-213.
- Zhang, Q., & Li, F. (2013). Combating P-glycoprotein-mediated multidrug resistance using therapeutic nanoparticles. *Curr. Pharm. Des.* **19**(37): 6655-6666.
- Zhang, X. G., Gaillard, J. P., Robillard, N., Lu, Z. Y., Gu, Z. J., Jourdan, M., Boiron, J. M., Bataille, R., & Klein, B. (1994). Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. *Blood* **83**(12): 3654-3663.
- Zhang, Y. A., Nemunaitis, J., Samuel, S. K., Chen, P., Shen, Y., & Tong, A. W. (2006). Antitumour activity of an oncolytic adenovirus-delivered oncogene small interfering RNA. *Cancer Res.* **66**(19): 9736-9743.
- Zhu, N. L., Asahina, K., Wang, J., Ueno, A., Lazaro, R., Miyaoka, Y., Miyajima, A., & Tsukamoto, H. (2012). Hepatic stellate cell-derived delta-like homolog 1 (DLK1) protein in liver regeneration. *J. Biol. Chem.* **287**(13): 10355-10367.
- Zonder, J. A., Mohrbacher, A. F., Singhal, S., van Rhee, F., Bensinger, W. I., Ding, H., Fry, J., Afar, D. E., & Singhal, A. K. (2012). A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. *Blood* **120**(3): 552-559.
- Zorde Khvalevsky, E., Gabai, R., Rachmut, I. H., Horwitz, E., Brunshwig, Z., Orbach, A., Shemi, A., Golan, T., Domb, A. J., Yavin, E., Giladi, H., Rivkin, L., Simerzin, A., Eliakim, R., Khalaileh, A., Hubert, A., Lahav, M., Kopelman, Y., Goldin, E., Dancour, A., Hants, Y., Arbel-Alon, S., Abramovitch, R., & Galun, E. (2013). Mutant KRAS is a druggable target for pancreatic cancer. *Proc Natl Acad Sci U S A* **110**(51): 20723-20728.